var title_f11_61_12240="Type II supracondylar fracture 2";
var content_f11_61_12240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gartland type II supracondylar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type II extension supracondylar humeral fracture (left elbow). Lateral radiograph. Note the positive fat pad sign (arrows) and how the anterior humeral line does not intersect with the capitellar epiphysis (black vertical line). A, ulna; B, humerus; C, capitellar epiphysis; D, radial head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koval KJ, Zuckerman JD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12240=[""].join("\n");
var outline_f11_61_12240=null;
var title_f11_61_12241="Aspiration of chancroid bubo";
var content_f11_61_12241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspiration of a chancroid bubo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aspiration of purulent fluid (seen in the syringe) from a fluctuant bubo in a patient with chancroid. Repeated needle aspirations may be necessary, even after effective antimicrobial therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12241=[""].join("\n");
var outline_f11_61_12241=null;
var title_f11_61_12242="Patient information: Juvenile rheumatoid arthritis (The Basics)";
var content_f11_61_12242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/13/26833\">",
"         Patient information: Uveitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/40/27266\">",
"         Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/23/37235\">",
"         Patient information: Fever in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Juvenile rheumatoid arthritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/juvenile-rheumatoid-arthritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27200776\">",
"      <span class=\"h1\">",
"       What is juvenile rheumatoid arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Juvenile rheumatoid arthritis (also called &ldquo;juvenile idiopathic arthritis&rdquo;) is a condition that can cause stiff or swollen joints, pain, and other symptoms in children. Arthritis is a medical term for inflammation of the joints.",
"     </p>",
"     <p>",
"      There are several different types of this condition. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Systemic arthritis &ndash; This type happens when the body&rsquo;s infection-fighting system, called the &ldquo;immune system,&rdquo; attacks the joints. It also causes a fever and rash. Children age 1 to 16 can get systemic arthritis. It is just as common in boys as in girls.",
"       </li>",
"       <li>",
"        Polyarthritis &ndash; This type affects more than 4 joints after the child has it for 6 months. It is more common in girls than in boys.",
"       </li>",
"       <li>",
"        Pauciarthritis &ndash; This type affects less than 5 different joints after the child has it for 6 months. It is the most common type of juvenile arthritis. About half of children who have juvenile arthritis have this type. It is more common in girls, and usually starts at age 2 to 3. Children 10 and older rarely get it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200791\">",
"      <span class=\"h1\">",
"       What are the symptoms of juvenile rheumatoid arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever &ndash; Children who have systemic arthritis sometimes get a fever at the same time every day for 2 weeks or more. The fever can go away but come back around the same time the next day. &nbsp;",
"       </li>",
"       <li>",
"        Rash &ndash; Children who have systemic arthritis sometimes get a rash. The rash is made up of small pink patches. It can be easy to see when the child has a fever. The rash might go away when the fever goes down and start again when the fever comes back. &nbsp;",
"       </li>",
"       <li>",
"        Pain, stiffness, and swelling in the joints",
"       </li>",
"       <li>",
"        This can happen in the wrists, elbows, knees, and ankles. It can also be in the hands, hips, upper back, and jaw. &nbsp;",
"       </li>",
"       <li>",
"        Arthritis sometimes happens in the same joint on both sides of the body. For example, it might happen in both knees or both wrists.",
"       </li>",
"       <li>",
"        Some children have a stiff or swollen joint that does not hurt. For example, a child might &ldquo;walk funny&rdquo; in the morning, but get better after a little while.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200806\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has a stiff, swollen, or painful joint, see a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200821\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will do an exam and ask about your child&rsquo;s symptoms. Many other conditions cause symptoms similar to juvenile arthritis. These include infections, cancer, and other diseases. The doctor or nurse can order blood tests to see your child has a different condition.",
"     </p>",
"     <p>",
"      Some children with juvenile arthritis get an eye disease called &ldquo;uveitis.&rdquo; This is an inflammation inside the eye. Often, uveitis does not cause symptoms until it has damaged the eye. A child who has juvenile arthritis might need to see an eye doctor to check for uveitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200838\">",
"      <span class=\"h1\">",
"       How is juvenile rheumatoid arthritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Doctors use several different medicines to treat arthritis in children. These can help joint pain and stiffness. They can also treat fever, rash, and other symptoms. Medicines can include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Medicines called NSAIDs, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        &nbsp;(sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        &nbsp;(sample brand names: Aleve&reg;, Naprosyn&reg;)",
"       </li>",
"       <li>",
"        Other medicines that come in pills",
"       </li>",
"       <li>",
"        Medicines given as a shot into joints",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors might also recommend:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Physical therapy, if the arthritis causes muscle problems",
"       </li>",
"       <li>",
"        Medicines to treat problems caused by the arthritis, such as uveitis or growth problems",
"       </li>",
"       <li>",
"        Surgery to fix problems caused by the arthritis, such as having 1 leg that is longer than the other",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200853\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=see_link\">",
"       Patient information: Uveitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       Patient information: Fever in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/61/12242?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83288 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12242=[""].join("\n");
var outline_f11_61_12242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200776\">",
"      What is juvenile rheumatoid arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200791\">",
"      What are the symptoms of juvenile rheumatoid arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200806\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200821\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200838\">",
"      How is juvenile rheumatoid arthritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200853\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/13/26833?source=related_link\">",
"      Patient information: Uveitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_61_12243="Paraneoplastic pemphigus bullae";
var content_f11_61_12243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles and flaccid bullae are present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12243=[""].join("\n");
var outline_f11_61_12243=null;
var title_f11_61_12244="HACE MRI";
var content_f11_61_12244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HACE MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With HACE, MRI reveals characteristic intense T2 signal in the white matter, especially the splenium of the corpus callosum, with no grey matter lesions. The MRI may remain abnormal for days to weeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Peter Hackett, MD. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12244=[""].join("\n");
var outline_f11_61_12244=null;
var title_f11_61_12245="Overview of upper extremity peripheral artery disease";
var content_f11_61_12245=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of upper extremity peripheral artery disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12245/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12245/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/61/12245/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with peripheral artery disease (PAD) have atherosclerotic disease of the lower extremity. However, PAD of the upper extremity is not rare and, when present, can manifest with limiting symptoms. Patients with compromise of blood flow to the extremities can present with typical ischemic pain of one or more muscle groups, atypical pain, or no symptoms. Patients with upper extremity peripheral artery disease can have upper-extremity exercise-induced pain. Exercise-induced pain is defined as a reproducible discomfort of a defined group of muscles induced by exercise and relieved with rest due to an imbalance between supply and demand of blood flow. The manifestations of upper extremity peripheral artery disease will be reviewed. Lower extremity peripheral artery disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63381581\">",
"    <span class=\"h1\">",
"     UPPER EXTREMITY ARTERIAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subclavian arteries provide blood flow to the upper extremities. On the left, the subclavian artery originates directly from the aorta distal to the left common carotid artery. On the right, blood flows first through the innominate artery, which divides into the right common carotid artery and right subclavian artery. The anatomy of the aortic arch can vary (",
"    <a class=\"graphic graphic_figure graphicRef54048 \" href=\"UTD.htm?5/47/5878\">",
"     figure 1",
"    </a>",
"    ) and may include an anomalous origin of the subclavian arteries. Retroesophageal subclavian vessels may compress the esophagus causing dysphagia, but the vessel may also be compressed leading to upper extremity ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of dysphagia in adults\", section on 'Cardiovascular abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vertebral arteries most often arise bilaterally as the first branch of the subclavian artery. In approximately 6 percent of patients, the vertebral artery, especially the left, may originate directly from the aortic arch [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/1\">",
"     1",
"    </a>",
"    ]. The subclavian artery passes over the first rib posterior to the anterior scalene muscle (",
"    <a class=\"graphic graphic_figure graphicRef65131 \" href=\"UTD.htm?5/14/5353\">",
"     figure 2",
"    </a>",
"    ) and becomes the axillary artery at the lateral margin of the first rib. The axillary artery becomes the brachial artery (",
"    <a class=\"graphic graphic_figure graphicRef71903 \" href=\"UTD.htm?14/37/14931\">",
"     figure 3",
"    </a>",
"    ) at the lower margin of the teres major muscle. The brachial artery passes between the biceps and triceps muscles accompanied by the ulnar and median nerves adjacent to the humerus and supplies the soft tissues of the arm. In the antecubital fossa, the brachial artery divides (",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"     figure 4",
"    </a>",
"    ) into the radial, interosseus, and ulnar arteries to supply soft tissues of the forearm. Distally at the wrist, the ulnar artery and radial artery supply the hand (",
"    <a class=\"graphic graphic_figure graphicRef69097 \" href=\"UTD.htm?1/31/1527\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The collateral circulation around the shoulder is usually sufficient such that flow around a focal area of stenosis in the subclavian artery is well-compensated (",
"    <a class=\"graphic graphic_figure graphicRef66933 \" href=\"UTD.htm?18/1/18454\">",
"     figure 6",
"    </a>",
"    ). When the proximal subclavian artery is occluded, blood flow is maintained to the arm via connections between the superior and inferior thyroid arteries; vertebral arteries, intercostals, superior epigastric, and internal thoracic arteries; profunda cervicis and descending branch of the occipital artery; scapular branches of the thyrocervical trunk and the branches of the axillary artery; and the thoracic branches of the axillary artery with the aortic intercostals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with upper extremity peripheral artery disease are asymptomatic, and detected only by the finding of asymmetric arm blood pressures. &nbsp;However, stenosis or occlusion of the proximal upper extremity arteries can lead to symptoms of arm pain with exertion, evidence of distal thromboembolism, acute limb ischemia or chronic ischemic symptoms (ischemic rest pain, digit ulceration).",
"   </p>",
"   <p>",
"    Patients who develop dizziness, or even syncope, during arm exertion may have retrograde blood flow in the vertebral artery to supply the demand of the arm skeletal muscle in the setting of reduced subclavian artery blood flow due to a proximal occlusion. This is referred to as \"subclavian steal syndrome.\" The clinical manifestations and treatment of subclavian steal syndrome are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H2#H2\">",
"     \"Subclavian steal syndrome\", section on 'Physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who presents with a differential blood pressure in the setting of acute chest pain, however, should be evaluated for an acute aortic syndrome (eg, aortic dissection) or, if the patient has had a prior cardiac bypass, coronary-subclavian steal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H3#H3\">",
"     \"Subclavian steal syndrome\", section on 'Coronary-subclavian steal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of upper extremity arterial stenosis may be suspected when a blood pressure difference between the arms is identified during evaluation of vital signs on routine physical examination. A difference in systolic blood pressure of &ge;10 mmHg is associated with peripheral artery disease (cerebrovascular, coronary artery, lower extremity, upper extremity) with low sensitivity but high specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/3-13\">",
"     3-13",
"    </a>",
"    ]. A systematic review identified studies that evaluated differences in upper extremity blood pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/13\">",
"     13",
"    </a>",
"    ]. A difference &ge;10 mmHg between the upper extremities significantly increased the risk of having a more than 50 percent subclavian stenosis in a pooled analysis of two arteriography studies (risk ratio [RR] 8.8, 95% CI 3.6-21.2). In a pooled analysis of noninvasive studies, a difference of &ge;15 mmHg between the upper extremities was associated with lower extremity peripheral artery disease (RR 2.4, 95% CI 1.5-3.9). An upper extremity pressure differential &ge;10 mmHg was predictive of preexisting cerebrovascular disease, increased cardiovascular mortality, and all-cause mortality.",
"   </p>",
"   <p>",
"    The blood pressure differential in the upper extremity can be confirmed in the vascular laboratory and the specific site and severity of stenosis or occlusion identified with segmental arm pressures and duplex ultrasound. With duplex, the ultrasound waveform distal to a proximal stenosis will demonstrate a blunted waveform. If the vessel is occluded, no blood flow will be seen but collateral vessels may be apparent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58549402#H58549402\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Wrist-brachial index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H146789830#H146789830\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Upper extremity segmental pressures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58548990#H58548990\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Duplex imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient is symptomatic and the diagnosis remains in question, computed tomographic (CT) angiography, magnetic resonance (MR) angiography or digital subtraction arteriography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54708 \" href=\"UTD.htm?24/61/25555\">",
"     image 1",
"    </a>",
"    ) may be indicated to establish the diagnosis.",
"   </p>",
"   <p>",
"    Atherosclerosis is the most common cause of ischemic upper extremity disease (",
"    <a class=\"graphic graphic_table graphicRef75926 \" href=\"UTD.htm?25/35/26172\">",
"     table 1",
"    </a>",
"    ), but other causes of upper extremity ischemia include large artery diseases such as arterial injury, arterial dissection, thrombosed aneurysm, atheroembolism, thromboembolism, fibrodysplasia, and arteritis (eg, Takayasu disease, giant cell arteritis), repetitive arterial injury (thoracic outlet syndrome, crutch injury) and small vessel diseases such as vasculitis, occupational injury, sequela of radiation therapy and disorders related to vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity peripheral artery disease is often associated with atherosclerosis involving other large vessels, particularly the carotid, coronary and lower extremity arteries. One study using baseline and longitudinal data for three cohorts that included 1778 participants found that subclavian stenosis predicted total and cardiovascular disease mortality independent of both cardiovascular risk factors and existent cardiovascular disease at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/9\">",
"     9",
"    </a>",
"    ]. In another study, the prevalence of subclavian artery stenosis in patients undergoing myocardial revascularization was reported in the 0.5 to 1.0 percent range [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12245/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the detection of upper extremity peripheral artery disease identifies patients at increased risk for stroke and cardiovascular disease and who may benefit from secondary prevention measures such as the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Control of hypertension",
"     </li>",
"     <li>",
"      Lipid modification",
"     </li>",
"     <li>",
"      Glycemic control in diabetes",
"     </li>",
"     <li>",
"      Smoking cessation",
"     </li>",
"     <li>",
"      Therapeutic lifestyle changes",
"     </li>",
"     <li>",
"      Antithrombotic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factor modification and secondary prevention of cardiovascular disease and stroke are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of claudication\", section on 'Risk factor modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not have symptoms do not require intervention. Options for the treatment of symptomatic subclavian stenosis or occlusion include surgical revascularization (eg, carotid-subclavian bypass, subclavian transposition) and percutaneous transluminal angioplasty and stenting. Percutaneous catheter-based treatment is less invasive and associated with lower complication rates, and shorter hospitalization. The treatment of symptoms of subclavian steal syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H15#H15\">",
"     \"Subclavian steal syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63380944\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although symptoms due to peripheral artery disease (PAD) are more common in the lower extremities, upper-extremity exercise-induced pain, pain at rest, and even tissue loss may also manifest in the upper extremities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The subclavian arteries provide blood flow to the upper extremities. On the left, the subclavian artery originates directly from the aorta distal to the left common carotid artery. On the right, blood flows first through the innominate artery, which divides into the right common carotid artery and right subclavian artery. The collateral circulation around the shoulder is usually sufficient such that flow around a focal area of stenosis in the subclavian artery is well tolerated. (See",
"      <a class=\"local\" href=\"#H63381581\">",
"       'Upper extremity arterial anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with upper extremity peripheral artery disease have few to no symptoms and manifest only with a difference in the systolic blood pressure between one arm and the other. However, stenosis or occlusion of the upper extremity arteries can lead to symptoms of arm pain with exertion, evidence of distal thromboembolism, acute limb ischemia or chronic ischemic symptoms (ischemic rest pain, digit ulceration). Patients who develop dizziness, or even syncope, during arm exertion and retrograde blood flow in the vertebral artery have \"subclavian steal syndrome.\" (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atherosclerosis is the most common cause of ischemic upper extremity disease (",
"      <a class=\"graphic graphic_table graphicRef75926 \" href=\"UTD.htm?25/35/26172\">",
"       table 1",
"      </a>",
"      ), but other causes of upper extremity ischemia include small artery diseases (eg, vasculitis, disorders related to vasoconstriction) and large artery diseases such as arterial injury, arterial dissection, thrombosed aneurysm, atheroembolism, thromboembolism, fibrodysplasia, arteritis (eg, Takayasu disease, giant cell arteritis), and repetitive arterial injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upper extremity peripheral artery disease is often associated with atherosclerosis involving other large vessels, particularly the carotid, coronary and lower extremity arteries. Thus, similar to the identification of lower extremity peripheral artery disease, the detection of upper extremity peripheral artery disease identifies patients at increased risk for stroke and cardiovascular disease and who may benefit from secondary prevention measures such as control of smoking cessation, control of hypertension, lipid modification, control of blood sugar and antithrombotic therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/1\">",
"      Cloud GC, Markus HS. Diagnosis and management of vertebral artery stenosis. Q J Med 2003; 96:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/2\">",
"      Levin PM, Rich NM, Hutton JE Jr. Collaternal circulation in arterial injuries. Arch Surg 1971; 102:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/3\">",
"      Baribeau Y, Westbrook BM, Charlesworth DC, et al. Brachial gradient in cardiac surgical patients. Circulation 2002; 106:I11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/4\">",
"      English JA, Carell ES, Guidera SA, Tripp HF. Angiographic prevalence and clinical predictors of left subclavian stenosis in patients undergoing diagnostic cardiac catheterization. Catheter Cardiovasc Interv 2001; 54:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/5\">",
"      Osborn LA, Vernon SM, Reynolds B, et al. Screening for subclavian artery stenosis in patients who are candidates for coronary bypass surgery. Catheter Cardiovasc Interv 2002; 56:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/6\">",
"      Calligaro KD, Ascer E, Veith FJ, et al. Unsuspected inflow disease in candidates for axillofemoral bypass operations: a prospective study. J Vasc Surg 1990; 11:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/7\">",
"      Shadman R, Criqui MH, Bundens WP, et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol 2004; 44:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/8\">",
"      Clark CE, Campbell JL, Powell RJ, Thompson JF. The inter-arm blood pressure difference and peripheral vascular disease: cross-sectional study. Fam Pract 2007; 24:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/9\">",
"      Aboyans V, Criqui MH, McDermott MM, et al. The vital prognosis of subclavian stenosis. J Am Coll Cardiol 2007; 49:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/10\">",
"      Clark CE, Campbell JL, Powell RJ. The interarm blood pressure difference as predictor of cardiovascular events in patients with hypertension in primary care: cohort study. J Hum Hypertens 2007; 21:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/11\">",
"      Igarashi Y, Chikamori T, Tomiyama H, et al. Clinical significance of inter-arm pressure difference and ankle-brachial pressure index in patients with suspected coronary artery disease. J Cardiol 2007; 50:281.",
"     </a>",
"    </li>",
"    <li>",
"     Clark CE, Githens-Mazer G, Rowley J, Shore AC, Hattersley A, Campbell JL. Systolic inter-arm blood pressure diff erence is associated with peripheral vascular disease in people with diabetes in primary care. Diabet Med 2010; 27 (suppl 1): 44",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/13\">",
"      Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012; 379:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/14\">",
"      Durham JR, Yao JS, Pearce WH, et al. Arterial injuries in the thoracic outlet syndrome. J Vasc Surg 1995; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/15\">",
"      Rubin DI, Schomberg PJ, Shepherd RF, Panneton JM. Arteritis and brachial plexus neuropathy as delayed complications of radiation therapy. Mayo Clin Proc 2001; 76:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12245/abstract/16\">",
"      Olsen, CO, Dunton, RF, Maggs, PR, Lahey, SJ. Review of coronary-subclavian steal following internal mammary artery-coronary bypass surgery. Ann Thorac Surg 1988; 48:887.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8216 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-201.248.109.99-7E3FD85ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12245=[""].join("\n");
var outline_f11_61_12245=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H63380944\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63381581\">",
"      UPPER EXTREMITY ARTERIAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63380944\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8216|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/61/25555\" title=\"diagnostic image 1\">",
"      Innominate artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8216|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/47/5878\" title=\"figure 1\">",
"      Variations of aortic arch branching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/14/5353\" title=\"figure 2\">",
"      Anterior neck anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/37/14931\" title=\"figure 3\">",
"      Anterior view of proximal humerus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/52/23365\" title=\"figure 4\">",
"      Major arteries and nerves of the anterior elbow region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/31/1527\" title=\"figure 5\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/1/18454\" title=\"figure 6\">",
"      Collateral circulation around the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8216|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/35/26172\" title=\"table 1\">",
"      Etiology of upper extremity ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=related_link\">",
"      Subclavian steal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_61_12246="HUS Vascular I";
var content_f11_61_12246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy showing thrombotic microangiopathy with subintimal fibrin deposition in an interlobular artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subintimal fibrin deposition without inflammation (arrow) in an interlobular artery as can be seen acutely in any of the forms of the hemolytic-uremic syndrome, including scleroderma. The marked narrowing of the vascular lumen will diminish distal perfusion, potentially leading to tissue necrosis if there is near total or total occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12246=[""].join("\n");
var outline_f11_61_12246=null;
var title_f11_61_12247="Causes and diagnosis of unilateral diaphragmatic paralysis and eventration";
var content_f11_61_12247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and diagnosis of unilateral diaphragmatic paralysis and eventration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12247/contributors\">",
"     Bartolome R Celli, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12247/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12247/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/61/12247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17480728\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilation depends upon the ability of the respiratory pump to move air in and out of the gas exchanging portion of the lungs. The dome-shaped diaphragm is the chief muscle of inspiration and the most powerful of the respiratory muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The other main muscles of inspiration are the scalenes, external intercostals, and sternomastoids. The muscles of expiration are the internal intercostals and the muscles of the abdominal wall (including the rectus abdominus, internal and external obliques, and transversus abdominus). Normal diaphragmatic function is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Normal diaphragm function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its role in the respiratory pump, the diaphragm also serves as a mechanical barrier between the abdominal and thoracic cavities and maintains the pressure gradient between the cavities.",
"   </p>",
"   <p>",
"    The causes and diagnostic evaluation of unilateral diaphragmatic paralysis and diaphragmatic eventration in adults will be reviewed here. The clinical manifestations and evaluation of respiratory muscle weakness due to neuromuscular disease, the evaluation and management of bilateral diaphragmatic paralysis in adults, disorders of control of ventilation, and the evaluation and management of diaphragm paralysis in the newborn are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=see_link\">",
"     \"Disorders of ventilatory control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=see_link\">",
"     \"Diaphragmatic paralysis in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link\">",
"     \"Treatment of diaphragmatic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17482173\">",
"    <span class=\"h1\">",
"     ALTERED FUNCTION WITH UNILATERAL DIAPHRAGM PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left and right sides of the diaphragm are innervated by the ipsilateral phrenic nerves, which derive from cervical nerve roots three, four, and five [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/4\">",
"     4",
"    </a>",
"    ]. Each nerve divides into four trunks that innervate the anterolateral, posterolateral, sternal, and crural portions of the diaphragm. Interruption or injury to one of the phrenic nerves results in unilateral diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Normal diaphragmatic structure and function are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Normal diaphragm function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the degree of diaphragmatic compromise, the other hemidiaphragm or the accessory muscles of respiration assume some or all the work of breathing. This compensation is achieved by more intense contraction of the accessory muscles and by the progressive recruitment of other, less important accessory inspiratory muscles (sternomastoid, trapezius, latissimus dorsi, and pectoralis minor and major). Patients may also recruit abdominal muscles to augment exhalation, which forces the respiratory system to a low volume (below functional residual capacity) at end-exhalation. The low volume increases the elastic recoil energy in the chest wall, assisting the next inspiration.",
"   </p>",
"   <p>",
"    In the case of unilateral diaphragm paralysis, the normal contralateral hemidiaphragm is able to generate enough negative pleural pressure to promote inspiration. The negative intrapleural pressure draws air in through the trachea, but also draws some air across the chest from the side of the paralyzed hemidiaphragm. As the paralyzed hemidiaphragm is pliable and mobile, it moves up into the chest (paradoxically) during inspiration. The movement of air from one lung to the other increases the work of breathing without improving gas exchange. However, over time (approximately one year) the paralyzed hemidiaphragm becomes less pliant and less responsive to the pull of negative pleural pressure from the contralateral side. The decreased compliance of the paralyzed hemidiaphragm reduces the amount of airflow from the paralyzed to the normal side. Thus, the respiratory impairment of unilateral diaphragm paralysis tends to improve even without restoration of phrenic nerve function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481150\">",
"    <span class=\"h1\">",
"     UNILATERAL DIAPHRAGMATIC PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral diaphragmatic paralysis is more common than bilateral disease. It is often discovered incidentally on a chest radiograph obtained for some other reason (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63905 \" href=\"UTD.htm?3/61/4051\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481157\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The list of causes of unilateral diaphragmatic paralysis is similar to that of bilateral involvement, but the proportional likelihood of each of the causes changes and intrathoracic disease or injury of the phrenic nerve is added to the list.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phrenic nerve injury due to stretching or cooling during cardiac surgery is a common etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=see_link&amp;anchor=H21#H21\">",
"       \"Neurologic complications of cardiac surgery\", section on 'Phrenic nerve'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpes zoster, poliomyelitis, and other viral infections have been associated with unilateral diaphragmatic paralysis.",
"     </li>",
"     <li>",
"      Cervical spondylosis, cervical compressive tumors, blunt neck trauma, neck surgery, pneumonia, and iatrogenic embolization are infrequent causes of unilateral diaphragm paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a minority of patients with neuralgic amyotrophy, an inflammatory disorder of the brachial plexus, the phrenic nerve is affected, causing diaphragmatic weakness or paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/13\">",
"       13",
"      </a>",
"      ]. A related condition, hereditary brachial plexopathy (MIM 162100) can also be associated with phrenic nerve weakness. Diaphragm paralysis complicates about 5 percent of congenital brachial plexus palsies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H13#H13\">",
"       \"Brachial plexus syndromes\", section on 'Neuralgic amyotrophy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H18#H18\">",
"       \"Brachial plexus syndromes\", section on 'Hereditary brachial plexopathy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=see_link&amp;anchor=H10#H10\">",
"       \"Diaphragmatic paralysis in the newborn\", section on 'Birth injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As is the case for bilateral disease, many cases of unilateral diaphragmatic paralysis are idiopathic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481164\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unilateral diaphragmatic paralysis are usually",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    at rest, but may have exertional dyspnea and decreased exercise performance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. However, patients with underlying or intercurrent lung disease may experience dyspnea at rest. Orthopnea can also occur, but is not as intense as with bilateral diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. Unilateral diaphragm paralysis may also be associated with sleep-disordered breathing during rapid eye movement sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are asked about any history of childhood poliomyelitis, cardiac surgery (especially if the paralysis is left-sided), or chest irradiation and also pain, injury, manipulation, surgery, or irradiation of the neck or cervical spine (",
"    <a class=\"graphic graphic_table graphicRef74792 \" href=\"UTD.htm?28/18/28972\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If parenchymal lung disease develops (eg, pneumonia, COPD exacerbation), the increase in load may fatigue the already overburdened accessory muscles, leading to symptoms and signs of ventilatory failure. Respiratory insufficiency in this setting is often reversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H2#H2\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481171\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to bilateral diaphragmatic paralysis, the diagnosis of unilateral paralysis is usually suggested by typical findings on the upright chest radiograph and confirmed by fluoroscopic evaluation. Pulmonary function testing provides supportive evidence of inspiratory muscle weakness, a measure of the degree of respiratory impairment, and a benchmark for future comparisons. The differential diagnosis of unilateral diaphragmatic paralysis includes a subpulmonic pleural effusion, diaphragmatic eventration, diaphragmatic hernia, and unilateral subdiaphragmatic processes (eg, abscess, splenomegaly).",
"   </p>",
"   <p>",
"    Electromyography and measurement of transdiaphragmatic pressures are not necessary for routine management of unilateral diaphragmatic weakness, unless the patient is incapacitated enough to consider surgical treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of diaphragmatic paralysis\", section on 'Unilateral paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27378083\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, laboratory testing in the setting of unilateral diaphragmatic paralysis is nonspecific, particularly when the history and physical examination do not suggest a systemic neuromuscular disease. We obtain a complete blood count to assess whether anemia is playing a role in dyspnea. Thyroid tests are reasonable, although thyroid disease is more commonly associated with bilateral diaphragmatic than unilateral weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481178\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frontal, upright chest radiograph that shows an elevated hemidiaphragm is sensitive, but not specific for the diagnosis of unilateral diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/17\">",
"     17",
"    </a>",
"    ]. The diagnosis can be easily confirmed with a fluoroscopic &ldquo;sniff&rdquo; test, in which diaphragmatic movement is observed fluoroscopically while the patient sniffs forcefully [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/18\">",
"     18",
"    </a>",
"    ]. The sniff test shows paradoxical elevation of the paralyzed hemidiaphragm with inspiration compared with the rapid descent of the normal hemidiaphragm. The sniff test is positive in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a diagnosis of unilateral diaphragmatic paralysis, computerized tomography of the thorax is obtained to evaluate the course of the ipsilateral phrenic nerve and exclude involvement by a tumor. Patchy areas of atelectasis may be noted at the lung base. For patients with a history of neck pain or injury, we obtain magnetic resonance imaging of the cervical spine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481185\">",
"    <span class=\"h3\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;When diaphragmatic weakness is suspected on the basis of dyspnea or an elevated hemidiaphragm, we typically obtain spirometry (in the supine and sitting positions), lung volumes, maximal inspiratory pressure, and maximal expiratory pressure. When unilateral diaphragmatic paralysis is present, the forced vital capacity (FVC) is usually decreased in the range of 70 to 80 percent of predicted values, a less pronounced reduction than seen with bilateral disease. The FVC may decrease further by 15 to 25 percent in the supine position. The deleterious effect of the supine position is more pronounced with paralysis of the right hemidiaphragm, possibly due to the larger proportion of lung function performed by the larger right lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The maximal inspiratory pressure (MIP) is usually decreased to values of 60 percent of predicted (normal values are more negative than -60 cm H2O). The maximal expiratory pressure (MEP) is usually normal. We do not routinely obtain maximum voluntary ventilation (MVV), unless needed for cardiopulmonary exercise testing. Similarly, we have not found sniff nasal pressures measured at the nose to provide additional information, although other authors use this test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, oxygen saturation is reduced in the supine position. In the absence of accompanying lung disease, it is unusual for the patient with unilateral diaphragmatic paralysis to develop an elevated arterial partial pressure of carbon dioxide (PaCO2) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481192\">",
"    <span class=\"h3\">",
"     Electromyography and physiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography (EMG) has a limited role in unilateral diaphragmatic paralysis; however, measurement of the pressure generated by the inspiratory muscles may be helpful. The performance of diaphragmatic electromyography and measurement of transdiaphragmatic pressure (Pdi) are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H26028764#H26028764\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Diaphragmatic electromyography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H26028725#H26028725\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Measurement of transdiaphragmatic pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The transdiaphragmatic pressure measured during a maximal inspiratory force (Pdi-max) is decreased in unilateral diaphragmatic paralysis. In addition, the gastric (Pga) component of the Pdi during tidal breathing is decreased, an effect that is more evident with paralysis of the left hemidiaphragm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H26028764#H26028764\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Diaphragmatic electromyography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=see_link&amp;anchor=H26028725#H26028725\">",
"     \"Causes and diagnosis of bilateral diaphragmatic paralysis\", section on 'Measurement of transdiaphragmatic pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481199\">",
"    <span class=\"h3\">",
"     Polysomnography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with neuromuscular disease, the presence of sleep-disordered breathing may be suspected on the basis of symptoms of sleep disturbance (eg, daytime sleepiness, fatigue) and the degree of abnormality on pulmonary function tests (eg, FVC or MIP &lt;50 percent of predicted) (",
"    <a class=\"graphic graphic_table graphicRef79606 \" href=\"UTD.htm?20/44/21195\">",
"     table 2",
"    </a>",
"    ). When sleep-disordered breathing is suspected, overnight multichannel polysomnography is obtained. Overnight pulse oximetry may be used as a screening test for nocturnal oxygen desaturation, but is generally not adequate screening for sleep-disordered breathing in these patients, as it underestimates the degree of hypoventilation and sleep disturbance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1382?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481206\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral diaphragmatic paralysis usually carries an excellent prognosis for survival, unless the paralysis is caused by an inherently fatal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the prognosis for recovery of diaphragmatic function is variable, and the exact proportion of patients who manifest improvement is unknown. Even those who do not recover diaphragm function generally lead a normal life, although breathlessness may occur during exercise or situations of increased ventilatory demands. Some patients with idiopathic diaphragm paralysis recover spontaneously over several months. A discussion of treatment options is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of diaphragmatic paralysis\", section on 'Unilateral paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481213\">",
"    <span class=\"h1\">",
"     EVENTRATION OF THE DIAPHRAGM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eventration of the diaphragm is a disorder in which all or part of the diaphragmatic muscle is replaced by fibroelastic tissue, leading to a thinned and pliable central portion of the diaphragm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481220\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eventration may be congenital or acquired; the congenital form reflects a failure of the fetal diaphragm to muscularize, whereas the acquired form is associated with phrenic nerve injury or is idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. The continuity of the diaphragm and normal attachments to the costal margin are maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43235?source=see_link\">",
"     \"Eventration of the diaphragm in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481227\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, diaphragmatic eventration is rarely symptomatic. When present, the symptoms associated with diaphragmatic eventration include dyspnea, palpitations, chest pain, dyspepsia, and recurrent pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12247/abstract/24\">",
"     24",
"    </a>",
"    ]. The degree of respiratory impairment ranges from the more common asymptomatic elevation of the diaphragmatic dome to the much less common degree of respiratory impairment seen in unilateral diaphragmatic paralysis. (See",
"    <a class=\"local\" href=\"#H17481164\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The severe congenital diaphragmatic eventration seen in newborns is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43235?source=see_link\">",
"     \"Eventration of the diaphragm in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481234\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of eventration is usually made on the basis of the presence of a localized area of elevation of the dome of the hemidiaphragm on an upright chest radiograph. The area of elevation corresponds to the weakened or fibrotic area of the hemidiaphragm, which is displaced into the hemithorax. The lateral view of the upright radiograph generally confirms a localized elevation of the dome of the hemidiaphragm with a smooth contour. When the eventration is more diffuse, the radiographic appearance is similar to that of unilateral diaphragmatic paralysis. (See",
"    <a class=\"local\" href=\"#H17481178\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Further evaluation is not necessary in asymptomatic patients. Pulmonary function tests are typically performed in those patients with exertional or recumbent dyspnea or when it is unclear if the problem is an eventration or unilateral paralysis. (See",
"    <a class=\"local\" href=\"#H17481185\">",
"     'Pulmonary function'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Fluoroscopy with sniff testing of a diaphragmatic eventration typically shows normal or slightly reduced diaphragmatic motion on the affected side. When the eventration is large, the hemidiaphragm may appear immobile on sniff testing. (See",
"    <a class=\"local\" href=\"#H17481178\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of an eventration includes unilateral diaphragmatic paralysis, subdiaphragmatic or diaphragmatic masses, and subpulmonic pleural fluid. In the case of a mass, the contour of the diaphragmatic defect is more likely irregular and not necessarily located at the dome. Diaphragmatic hernias are either anterior (Morgagni) or posterior (Bochdalek) and can usually be differentiated from an eventration on the lateral chest radiograph. Subpulmonic pleural fluid is usually associated with blunting of the costophrenic angles. If the diagnosis is unclear, a computed tomography scan of the thorax should provide differentiation of these entities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481736\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481848\">",
"    <span class=\"h2\">",
"     Unilateral diaphragmatic paralysis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unilateral diaphragmatic paralysis is more common than bilateral disease. It is often discovered incidentally on a chest radiograph obtained for some other reason. Causes of unilateral diaphragmatic paralysis in adults include phrenic nerve injury due to stretching or cooling during cardiac surgery, viral infections (eg, Herpes zoster, poliomyelitis), cervical spondylosis, cervical compressive tumors, blunt neck trauma or surgery, and brachial plexopathies (",
"      <a class=\"graphic graphic_table graphicRef74792 \" href=\"UTD.htm?28/18/28972\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17481157\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unilateral diaphragmatic paralysis are usually",
"      <strong>",
"       asymptomatic",
"      </strong>",
"      at rest, but may have dyspnea and decreased exercise performance with exertion. (See",
"      <a class=\"local\" href=\"#H17481164\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A frontal, upright chest radiograph that shows an elevated hemidiaphragm is a sensitive, but not specific test for the diagnosis of unilateral diaphragmatic paralysis. The key diagnostic test is the fluoroscopic &ldquo;sniff&rdquo; test, in which diaphragmatic movement is observed fluoroscopically while the patient sniffs forcefully. The normal hemidiaphragm descends briskly, while the paralyzed hemidiaphragm is drawn upwards. (See",
"      <a class=\"local\" href=\"#H17481178\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When diaphragmatic weakness is suspected on the basis of dyspnea or an elevated hemidiaphragm, we typically obtain spirometry (in the supine and sitting positions), lung volumes, maximal inspiratory pressure, and maximal expiratory pressure. The forced vital capacity (FVC) is usually decreased in the range of 70 to 80 percent of the predicted value, a less pronounced reduction than seen with bilateral disease. The FVC typically decreases further by 15 to 25 percent in the supine position. (See",
"      <a class=\"local\" href=\"#H17481185\">",
"       'Pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When sleep-disordered breathing is suspected on the basis of symptoms or the degree of respiratory impairment, overnight, multichannel polysomnography is obtained (",
"      <a class=\"graphic graphic_table graphicRef79606 \" href=\"UTD.htm?20/44/21195\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17481199\">",
"       'Polysomnography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of patients with unilateral diaphragmatic paralysis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of diaphragmatic paralysis\", section on 'Unilateral paralysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17481855\">",
"    <span class=\"h2\">",
"     Eventration of the diaphragm",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eventration of the diaphragm may be congenital or acquired; the congenital form reflects a failure of the fetal diaphragm to muscularize, whereas the acquired form is associated with phrenic nerve injury or idiopathic. (See",
"      <a class=\"local\" href=\"#H17481220\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adults with diaphragmatic eventration are asymptomatic, but some have exertional dyspnea. (See",
"      <a class=\"local\" href=\"#H17481227\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of diaphragmatic eventration is based on the upright frontal and lateral chest radiographs showing the typical finding of a localized area of elevation of the dome of the hemidiaphragm. The lateral view confirms the localized nature of the elevation of the dome of the hemidiaphragm and the smooth contour. When the eventration is more diffuse, the radiographic appearance is similar to that of unilateral diaphragmatic paralysis. (See",
"      <a class=\"local\" href=\"#H17481234\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation of diaphragmatic eventration is not necessary in asymptomatic patients. Pulmonary function tests are typically performed in those patients with exertional or recumbent dyspnea or when it is unclear if the problem is an eventration or unilateral paralysis. (See",
"      <a class=\"local\" href=\"#H17481234\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/1\">",
"      Roussos C, Macklem PT. The respiratory muscles. N Engl J Med 1982; 307:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/2\">",
"      Fell SC. Surgical anatomy of the diaphragm and the phrenic nerve. Chest Surg Clin N Am 1998; 8:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/3\">",
"      Rochester DF. The diaphragm: contractile properties and fatigue. J Clin Invest 1985; 75:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/4\">",
"      Maish MS. The diaphragm. Surg Clin North Am 2010; 90:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/5\">",
"      Davis J, Goldman M, Loh L, Casson M. Diaphragm function and alveolar hypoventilation. Q J Med 1976; 45:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/6\">",
"      Gibson GJ. Diaphragmatic paresis: pathophysiology, clinical features, and investigation. Thorax 1989; 44:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/7\">",
"      Laroche CM, Carroll N, Moxham J, Green M. Clinical significance of severe isolated diaphragm weakness. Am Rev Respir Dis 1988; 138:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/8\">",
"      Lisboa C, Par&eacute; PD, Pertuz&eacute; J, et al. Inspiratory muscle function in unilateral diaphragmatic paralysis. Am Rev Respir Dis 1986; 134:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/9\">",
"      Piehler JM, Pairolero PC, Gracey DR, Bernatz PE. Unexplained diaphragmatic paralysis: a harbinger of malignant disease? J Thorac Cardiovasc Surg 1982; 84:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/10\">",
"      Canbaz S, Turgut N, Halici U, et al. Electrophysiological evaluation of phrenic nerve injury during cardiac surgery--a prospective, controlled, clinical study. BMC Surg 2004; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/11\">",
"      Chapman SA, Holmes MD, Taylor DJ. Unilateral diaphragmatic paralysis following bronchial artery embolization for hemoptysis. Chest 2000; 118:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/12\">",
"      McCaul JA, Hislop WS. Transient hemi-diaphragmatic paralysis following neck surgery: report of a case and review of the literature. J R Coll Surg Edinb 2001; 46:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/13\">",
"      Tsao BE, Ostrovskiy DA, Wilbourn AJ, Shields RW Jr. Phrenic neuropathy due to neuralgic amyotrophy. Neurology 2006; 66:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/14\">",
"      Hart N, Nickol AH, Cramer D, et al. Effect of severe isolated unilateral and bilateral diaphragm weakness on exercise performance. Am J Respir Crit Care Med 2002; 165:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/15\">",
"      Sandham JD, Shaw DT, Guenter CA. Acute supine respiratory failure due to bilateral diaphragmatic paralysis. Chest 1977; 72:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/16\">",
"      Steier J, Jolley CJ, Seymour J, et al. Sleep-disordered breathing in unilateral diaphragm paralysis or severe weakness. Eur Respir J 2008; 32:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/17\">",
"      Chetta A, Rehman AK, Moxham J, et al. Chest radiography cannot predict diaphragm function. Respir Med 2005; 99:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/18\">",
"      Gierada DS, Slone RM, Fleishman MJ. Imaging evaluation of the diaphragm. Chest Surg Clin N Am 1998; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/19\">",
"      Alexander C. Diaphragm movements and the diagnosis of diaphragmatic paralysis. Clin Radiol 1966; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/20\">",
"      Steier J, Kaul S, Seymour J, et al. The value of multiple tests of respiratory muscle strength. Thorax 2007; 62:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/21\">",
"      Martinez FJ, Strawderman RL, Flaherty KR, et al. Respiratory response during arm elevation in isolated diaphragm weakness. Am J Respir Crit Care Med 1999; 160:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/22\">",
"      Qureshi A. Diaphragm paralysis. Semin Respir Crit Care Med 2009; 30:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/23\">",
"      Groth SS, Andrade RS. Diaphragmatic eventration. Thorac Surg Clin 2009; 19:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12247/abstract/24\">",
"      Mouroux J, Venissac N, Leo F, et al. Surgical treatment of diaphragmatic eventration using video-assisted thoracic surgery: a prospective study. Ann Thorac Surg 2005; 79:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16185 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12247=[""].join("\n");
var outline_f11_61_12247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17481736\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17480728\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17482173\">",
"      ALTERED FUNCTION WITH UNILATERAL DIAPHRAGM PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481150\">",
"      UNILATERAL DIAPHRAGMATIC PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481157\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481164\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481171\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27378083\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17481178\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17481185\">",
"      - Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17481192\">",
"      - Electromyography and physiologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17481199\">",
"      - Polysomnography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481206\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481213\">",
"      EVENTRATION OF THE DIAPHRAGM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481220\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481227\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481234\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17481736\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481848\">",
"      Unilateral diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17481855\">",
"      Eventration of the diaphragm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16185|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/61/4051\" title=\"diagnostic image 1\">",
"      Left hemidiaph paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16185|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/18/28972\" title=\"table 1\">",
"      Causes diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/44/21195\" title=\"table 2\">",
"      Sleep study indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14584?source=related_link\">",
"      Causes and diagnosis of bilateral diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=related_link\">",
"      Diaphragmatic paralysis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1382?source=related_link\">",
"      Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43235?source=related_link\">",
"      Eventration of the diaphragm in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3834?source=related_link\">",
"      Neurologic complications of cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=related_link\">",
"      Treatment of diaphragmatic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_61_12248="Kawasaki disease: Clinical features and diagnosis";
var content_f11_61_12248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Kawasaki disease: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12248/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/61/12248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/1\">",
"     1",
"    </a>",
"    ]. KD also occurs rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2\">",
"     2",
"    </a>",
"    ]. However, complications such as coronary artery aneurysms, depressed myocardial contractility and heart failure, myocardial infarction, arrhythmias, and peripheral arterial occlusion may develop and lead to significant morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of KD are discussed in this review. The epidemiology, etiology, treatment, and complications, including cardiac sequelae, of Kawasaki disease are presented separately. Incomplete (atypical) KD and unique features in infants and adults are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link\">",
"     \"Incomplete (atypical) Kawasaki disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16183?source=see_link\">",
"     \"Kawasaki disease: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of KD reflect widespread inflammation of medium- and small-sized blood vessels. Diagnosis is based upon evidence of systemic inflammation, as evidenced by fever, in association with signs of mucocutaneous inflammation. The characteristic bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, rash, extremity changes, and lymphadenopathy typically develop after a brief nonspecific prodrome of respiratory or gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. These clinical signs are the basis for the diagnostic criteria for KD (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucous membrane findings are seen in approximately 90 percent of cases of KD, polymorphous rash in 70 to 90 percent, extremity changes in 50 to 85 percent, ocular changes in &gt;75 percent, and cervical lymphadenopathy in 25 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/7,10-12\">",
"     7,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings are often not present at the same time. As an example, some patients have only developed fever and cervical lymphadenopathy by the time of admission (so-called KD with isolated cervical lymphadenopathy, KDiL) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/13\">",
"     13",
"    </a>",
"    ]. In one case series, these patients tended to be older and to have a more severe course, with increased risk of coronary artery disease and lack of response to intravenous immune globulin. Thus, repeated histories and physical examinations are important both for making a timely diagnosis of KD in children who fail to meet diagnostic criteria, as well as for appropriate consideration of alternative diagnoses. (See",
"    <a class=\"local\" href=\"#H26262883\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is the most consistent manifestation of KD. It reflects elevated levels of proinflammatory cytokines, such as tumor necrosis factor and interleukin-6, which are thought to mediate the underlying vascular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/14\">",
"     14",
"    </a>",
"    ]. Fever is minimally responsive to antipyretic agents, and it typically remains above 38.5&ordm;C during most of the illness. The diagnosis of KD should be considered in all children with prolonged unexplained fever &ge;five days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link\">",
"     \"Incomplete (atypical) Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral nonexudative conjunctivitis is present in more than 90 percent of patients. A predominantly bulbar injection typically begins within days of the onset of fever, and the eyes often have a brilliant erythema, which spares the limbus (",
"    <a class=\"graphic graphic_picture graphicRef78898 \" href=\"UTD.htm?15/1/15376\">",
"     picture 1",
"    </a>",
"    ). Children also are frequently photophobic, and anterior uveitis may develop [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Slit-lamp examination may be helpful in ambiguous cases; the presence of uveitis provides further evidence for the diagnosis of KD, since it is more commonly seen in KD than in other diseases with similar presentations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mucositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucositis often becomes evident as KD progresses. Cracked, red lips (",
"    <a class=\"graphic graphic_picture graphicRef59319 \" href=\"UTD.htm?19/34/20004\">",
"     picture 2",
"    </a>",
"    ) and a strawberry tongue (",
"    <a class=\"graphic graphic_picture graphicRef68321 \" href=\"UTD.htm?0/2/43\">",
"     picture 3",
"    </a>",
"    ) are characteristic; the latter is a result of sloughing of filiform papillae and denuding of the inflamed glossal tissue. Discrete oral lesions, such as vesicles or ulcers, and tonsillar exudate, are suggestive of a disease process other than KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous manifestations of KD are polymorphous. The rash typically begins as perineal erythema and desquamation, followed by macular, morbilliform, or targetoid skin lesions of the trunk and extremities. Vesicular or bullous lesions are rare, but KD may trigger a psoriasiform eruption in children not previously recognized to have psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extremity changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the extremities are generally the last manifestation to appear. Children develop an indurated edema of the dorsum of their hands and feet (",
"    <a class=\"graphic graphic_picture graphicRef72040 \" href=\"UTD.htm?25/12/25793\">",
"     picture 4",
"    </a>",
"    ), and a diffuse erythema of their palms and soles.",
"   </p>",
"   <p>",
"    The convalescent phase of KD is often characterized by sheet-like desquamation that begins in the periungual region of the hands and feet (",
"    <a class=\"graphic graphic_picture graphicRef53452 \" href=\"UTD.htm?5/29/5587\">",
"     picture 5",
"    </a>",
"    ), and by linear nail creases (Beau's lines). The prevalence of periungual desquamation in patients with KD has been reported to vary from 98 to 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/20\">",
"     20",
"    </a>",
"    ]. The lowest rate was documented in a retrospective review of patients treated at a tertiary center in the United States from 2003 to 2007. Factors that might have contributed to this lower prevalence than was seen in earlier reports include uniform treatment with high dose IVIG, and ethnic differences from Asian case series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/3,4,21,22\">",
"     3,4,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arthritis has been reported in 7.5 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The prevalence of arthritis was 7.5 percent in a retrospective Canadian study of 414 consecutive patients diagnosed with KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/23\">",
"     23",
"    </a>",
"    ]. The large joints (ie, knee, ankle, and hip) were primarily involved. Oligoarticular involvement (arthritis of four or fewer joints) occurred in 16 patients and polyarticular involvement (arthritis of five or more joints) in 15 patients. Patients with arthritis were more likely to have increased levels of inflammatory markers (C-reactive protein [CRP], or erythrocyte sedimentation rate [ESR]) and neutrophils. Otherwise, there were no differences in clinical features, response to therapy, or clinical outcome between patients with or without arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical lymphadenopathy is the least consistent feature of KD, absent in as many as half to three-quarters of children with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/11\">",
"     11",
"    </a>",
"    ]. When present, lymphadenopathy tends to involve primarily the anterior cervical nodes overlying the sternocleidomastoid muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/25\">",
"     25",
"    </a>",
"    ]. Diffuse lymphadenopathy or other signs of reticuloendothelial involvement (eg, splenomegaly) should prompt a search for alternative diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3460119\">",
"    <span class=\"h2\">",
"     Cardiovascular findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac manifestations during the first week to 10 days of illness may include tachycardia out of proportion to the degree of fever, gallop sounds, and muffled heart tones [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2\">",
"     2",
"    </a>",
"    ]. Severely ill patients, particularly young infants, may develop fusiform aneurysms of the brachial arteries that are easily palpable or visible in the axillae. In addition, young infants may have cold, pale, or cyanotic digits of the hands and feet due to reduced blood perfusion. Gangrene may, in rare cases, cause loss of fingers or toes during this acute period. Cardiovascular findings are not part of the classical diagnostic criteria",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following nonspecific symptoms commonly occur in children within the first 10 days before diagnosis of KD, but are not included in the diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea, vomiting, or abdominal pain &mdash; 61 percent",
"     </li>",
"     <li>",
"      Irritability &mdash; 50 percent",
"     </li>",
"     <li>",
"      Vomiting alone &mdash; 44 percent",
"     </li>",
"     <li>",
"      Cough or rhinorrhea &mdash; 35 percent",
"     </li>",
"     <li>",
"      Decreased intake &mdash; 37 percent",
"     </li>",
"     <li>",
"      Weakness &mdash; 19 percent",
"     </li>",
"     <li>",
"      Joint pain &mdash; 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No laboratory studies are included among the diagnostic criteria for typical KD. However, certain findings may support the diagnosis of KD, particularly in ambiguous cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H26262883\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link&amp;anchor=H2509284#H2509284\">",
"     \"Incomplete (atypical) Kawasaki disease\", section on 'Laboratory tests'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic inflammation is characteristic of KD. Typical manifestations include elevation of acute phase reactants (eg, C-reactive protein [CRP] or erythrocyte sedimentation rate [ESR]), leukocytosis, and a left-shift in the white blood cell count. Platelet counts generally rise by the second week of illness and may reach",
"      <span class=\"nowrap\">",
"       1,000,000/mm3",
"      </span>",
"      (reactive thrombocytosis) in the most severe cases.",
"     </li>",
"     <li>",
"      Children with KD often present with a normocytic, normochromic anemia. Hemoglobin concentrations more than two standard deviations below the mean for age are noted in one-half of patients within the first two weeks of illness (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"UTD.htm?5/34/5679\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Urinary microscopy commonly reveals white blood cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/26\">",
"       26",
"      </a>",
"      ]. Pyuria is often of urethral origin and therefore may be missed on urinalyses obtained by bladder tap or catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/27\">",
"       27",
"      </a>",
"      ]. In addition, white cells are mononuclear, and are not detected by dipstick tests for leukocyte esterase. Thus, children with suspected KD should have a clean voided or bagged urine specimen collected for microscopic examination.",
"     </li>",
"     <li>",
"      In one retrospective series of 259 patients, 45 percent had at least one abnormal liver function test [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/28\">",
"       28",
"      </a>",
"      ]. In a case-control series approximately 30 percent of 280 patients with KD had mild to moderate elevation of transaminases (eg, serum alanine aminotransferase &gt;50",
"      <span class=\"nowrap\">",
"       U/L)",
"      </span>",
"      because of intrahepatic congestion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, a minority of children develop obstructive jaundice from hydrops of the gallbladder.",
"     </li>",
"     <li>",
"      Cerebrospinal fluid (CSF) may display a mononuclear pleocytosis without hypoglycorrhachia or elevation of CSF protein. In a retrospective review, 46 of 520 children with KD underwent lumbar puncture [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/29\">",
"       29",
"      </a>",
"      ]. In this subset of patients, 39 percent had elevated CSF white cell counts. The median count was 22.5",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      with 6 percent neutrophils and 92 percent mononuclear cells, although cell counts as high as",
"      <span class=\"nowrap\">",
"       320/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      with up to 79 percent neutrophils were reported. In a small case series of 10 children with KD, elevated CSF inflammatory cytokines (ie, IL-6 and sTNFR1) were reported in addition to CSF pleocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, arthrocentesis of involved joints typically demonstrates a pleocytosis, with 125,000 to 300,000 white",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      primarily neutrophils [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with KD develop significant perturbations in serum lipid profiles, including elevated triglycerides and low density lipoproteins, and depressed high density lipoproteins [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2,32-34\">",
"       2,32-34",
"      </a>",
"      ]. A return to normal may take years in untreated children, but generally occurs within weeks or months following IVIG therapy.",
"     </li>",
"     <li>",
"      Hyponatremia (serum sodium &lt;135",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      may be seen and is associated with an increased risk of coronary artery aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26262883\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the diagnosis of KD were established by Tomisaku Kawasaki in 1967. Diagnosis of KD according to these criteria requires the presence of fever lasting &ge;five days, combined with at least four of the five following physical findings, without an alternative explanation (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/1,36\">",
"     1,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral bulbar conjunctival injection (",
"      <a class=\"graphic graphic_picture graphicRef78898 \" href=\"UTD.htm?15/1/15376\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oral mucous membrane changes, including injected or fissured lips (",
"      <a class=\"graphic graphic_picture graphicRef59319 \" href=\"UTD.htm?19/34/20004\">",
"       picture 2",
"      </a>",
"      ), injected pharynx, or strawberry tongue (",
"      <a class=\"graphic graphic_picture graphicRef68321 \" href=\"UTD.htm?0/2/43\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral extremity changes, including erythema of palms or soles, edema of hands or feet (acute phase) (",
"      <a class=\"graphic graphic_picture graphicRef72040 \" href=\"UTD.htm?25/12/25793\">",
"       picture 4",
"      </a>",
"      ), and periungual desquamation (convalescent phase) (",
"      <a class=\"graphic graphic_picture graphicRef53452 \" href=\"UTD.htm?5/29/5587\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Polymorphous rash",
"     </li>",
"     <li>",
"      Cervical lymphadenopathy (at least one lymph node &gt;1.5 cm in diameter)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Redness or crust formation at the site of Bacille Calmette-Guerin (BCG) inoculation is also suggested as a useful sign in several diagnostic guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. In one series of 15,524 patients with KD and a history of BCG vaccination, 50 percent had this finding, compared with none of the 53 children admitted with respiratory syncytial virus or rotavirus infection who served as the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with all clinical criteria, these are imperfect guidelines with less than 100 percent sensitivity and specificity. Children who do not meet the criteria may have an incomplete or atypical form of KD; algorithms published in 2004 form the basis for identifying such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, Dr. Kawasaki published his guidelines before cardiac involvement was recognized in this disease, so they were never intended to identify children at risk for developing coronary artery abnormalities. Thus, it is not surprising that at least 10 percent of children who develop coronary artery aneurysms never meet criteria for KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link\">",
"     \"Incomplete (atypical) Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, some patients who manifest five or six signs of KD may have other conditions. One study of patients referred for possible KD found that the standard clinical diagnostic criteria for KD were fulfilled in 18 of 39 patients (46 percent) in whom other diagnoses were established [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26263419\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26262954\">",
"    <span class=\"h2\">",
"     Delayed diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with IVIG within the first 10 days of illness reduces the prevalence of coronary artery aneurysms fivefold compared with children not treated with IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Thus, it is desirable to diagnose KD as soon as possible after the criteria are met (ie, not before the fifth day of illness), in order to initiate treatment and reduce the risk of coronary artery lesions. However, timely identification is challenging because the diagnosis is based upon nonspecific clinical signs and there is no definitive diagnostic test.",
"   </p>",
"   <p>",
"    In a retrospective study of 562 patients diagnosed with KD at eight North American centers, 92 cases (16 percent) were diagnosed after the first 10 days of illness (ie, late diagnosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/41\">",
"     41",
"    </a>",
"    ]. Predictors of a delay in diagnosis of KD included age below six months, clinical presentation of incomplete KD, greater distance from a tertiary center, and variability between clinical centers. In contrast, socioeconomic status was not associated with a delay in diagnosis.",
"   </p>",
"   <p>",
"    These findings suggest that practice variation in confirming a diagnosis of KD may in part contribute to a delayed diagnosis. The results of this study underscore the need for a high index of suspicion of KD, especially in young infants and patients who present with incomplete KD, in order to identify and treat patients in a timely manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link\">",
"     \"Incomplete (atypical) Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26263419\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;KD is most commonly confused with infectious exanthems of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2,42,43\">",
"     2,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infectious diseases and other mimics of KD may have the following clinical features not commonly found in KD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exudative conjunctivitis",
"     </li>",
"     <li>",
"      Exudative pharyngitis",
"     </li>",
"     <li>",
"      Discrete intraoral lesions",
"     </li>",
"     <li>",
"      Bullous or vesicular rash",
"     </li>",
"     <li>",
"      Generalized lymphadenopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any of these findings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the absence of fever should suggest a diagnosis other than KD. Of note, concurrent infections are common in patients with KD, found in up to 40 percent of patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/44\">",
"     44",
"    </a>",
"    ]. In this review of 129 consecutive children seen with KD in Toronto, infection at the time of diagnosis did not affect response to therapy or outcome. However, another series found that concomitant viral infection was associated with a higher frequency of coronary artery dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12248/abstract/45\">",
"     45",
"    </a>",
"    ]. In any event, diagnosis of an infectious condition does not preclude a concurrent diagnosis of KD.",
"   </p>",
"   <p>",
"    The differential diagnosis of KD includes (",
"    <a class=\"graphic graphic_table graphicRef53802 \" href=\"UTD.htm?6/10/6317\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measles, echovirus, adenovirus, and Epstein-Barr virus. These viral illnesses may share many of the signs of mucocutaneous inflammation, but they typically have less evidence of systemic inflammation and generally lack the extremity changes seen in KD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=see_link\">",
"       \"Clinical presentation and diagnosis of measles\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxin-mediated illnesses, especially group A streptococcal infections (eg, scarlet fever and toxic shock syndrome). These usually lack the ocular and articular involvement typical of KD, though patients with staphylococcal toxic shock syndrome occasionally may have conjunctival hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"       \"Staphylococcal toxic shock syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3944?source=see_link&amp;anchor=H8#H8\">",
"       \"Group A streptococcal (Streptococcus pyogenes) bacteremia in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rocky Mountain spotted fever and leptospirosis. Headache and gastrointestinal complaints typically are prominent features of these infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"       \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug reactions such as Stevens-Johnson syndrome or serum sickness. These may mimic KD, but with subtle differences in the ocular and mucosal manifestations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic onset juvenile idiopathic arthritis. Children with this condition generally lack the conjunctival and oral findings of KD. Lymphadenopathy also is generalized, unlike in KD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mercury hypersensitivity reaction (acrodynia). In particular, this shares certain clinical features with KD, including fever, rash, swelling of the palms and feet, desquamation, and photophobia. However, treatment of a child with possible KD should not be delayed while awaiting mercury levels, unless there is a convincing history of exposure to mercury, because of the rarity of acrodynia in the developed world. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology and toxicity of mercury\", section on 'Acrodynia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/8/3201?source=see_link\">",
"       \"Patient information: Kawasaki disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3458787\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood. KD also occurs rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kawasaki disease is characterized by systemic inflammation manifested by fever and mucocutaneous involvement, including bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, rash, extremity changes, and lymphadenopathy (",
"      <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"       table 1",
"      </a>",
"      ). These findings are often not present at the same time. Thus, repeated histories and physical examinations are important in making a timely diagnosis of KD in children with fever and signs of mucocutaneous inflammation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No laboratory studies are included among the diagnostic criteria for typical KD. However, certain findings may support the diagnosis of KD in ambiguous cases. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of KD according to classical criteria requires the presence of fever &ge;five days, combined with at least four of the other five signs of mucocutaneous inflammation, without any other explanation (",
"      <a class=\"graphic graphic_table graphicRef67711 \" href=\"UTD.htm?3/48/3851\">",
"       table 1",
"      </a>",
"      ). Incomplete KD, representing 20 to 60 percent of cases, is identified on the basis of additional clinical and laboratory features supportive of the diagnosis. (See",
"      <a class=\"local\" href=\"#H26262883\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link\">",
"       \"Incomplete (atypical) Kawasaki disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      KD is most commonly confused with infectious exanthems of childhood. The presence of clinical features not commonly found in KD, including exudative conjunctivitis, exudative pharyngitis, discrete intraoral lesions, bullous or vesicular rash,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      generalized lymphadenopathy, suggest another diagnosis (",
"      <a class=\"graphic graphic_table graphicRef53802 \" href=\"UTD.htm?6/10/6317\">",
"       table 3",
"      </a>",
"      ). Nonetheless, KD is sufficiently pleomorphic that none of these findings can definitively exclude the diagnosis. In addition, many children with KD also have concurrent infections. (See",
"      <a class=\"local\" href=\"#H26263419\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/1\">",
"      Burns JC, Glod&eacute; MP. Kawasaki syndrome. Lancet 2004; 364:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/2\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/3\">",
"      Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980; 65:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/4\">",
"      Huang GY, Ma XJ, Huang M, et al. Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002. J Epidemiol 2006; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/5\">",
"      Baker AL, Lu M, Minich LL, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr 2009; 154:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/6\">",
"      Burns JC, Mason WH, Glode MP, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991; 118:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/7\">",
"      Ozdemir H, Cift&ccedil;i E, Tapisiz A, et al. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. J Trop Pediatr 2010; 56:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/8\">",
"      Cai Z, Zuo R, Liu Y. Characteristics of Kawasaki disease in older children. Clin Pediatr (Phila) 2011; 50:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/9\">",
"      Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/10\">",
"      Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994; 83:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/11\">",
"      Sung RY, Ng YM, Choi KC, et al. Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease. Pediatr Infect Dis J 2006; 25:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/12\">",
"      Germain BF, Moroney JD, Guggino GS, et al. Anterior uveitis in Kawasaki disease. J Pediatr 1980; 97:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/13\">",
"      Nomura Y, Arata M, Koriyama C, et al. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission. J Pediatr 2010; 156:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/14\">",
"      Leung DY. The potential role of cytokine-mediated vascular endothelial activation in the pathogenesis of Kawasaki disease. Acta Paediatr Jpn 1991; 33:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/15\">",
"      Smith LB, Newburger JW, Burns JC. Kawasaki syndrome and the eye. Pediatr Infect Dis J 1989; 8:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/16\">",
"      Eberhard BA, Sundel RP, Newburger JW, et al. Psoriatic eruption in Kawasaki disease. J Pediatr 2000; 137:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/17\">",
"      Kishimoto S, Muneuchi J, Takahashi Y, et al. Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report. Acta Paediatr 2010; 99:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/18\">",
"      Ergin S, Karaduman A, Demirkaya E, et al. Plaque psoriasis induced after Kawasaki disease. Turk J Pediatr 2009; 51:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/19\">",
"      Liao YC, Lee JY. Psoriasis in a 3-month-old infant with Kawasaki disease. Dermatol Online J 2009; 15:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/20\">",
"      Wang S, Best BM, Burns JC. Periungual desquamation in patients with Kawasaki disease. Pediatr Infect Dis J 2009; 28:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/21\">",
"      Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/22\">",
"      Ichida F, Fatica NS, O'Loughlin JE, et al. Epidemiologic aspects of Kawasaki disease in a Manhattan hospital. Pediatrics 1989; 84:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/23\">",
"      Gong GW, McCrindle BW, Ching JC, Yeung RS. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr 2006; 148:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/24\">",
"      Melish ME. Kawasaki syndrome: a 1986 perspective. Rheum Dis Clin North Am 1987; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/25\">",
"      April MM, Burns JC, Newburger JW, Healy GB. Kawasaki disease and cervical adenopathy. Arch Otolaryngol Head Neck Surg 1989; 115:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/26\">",
"      Shike H, Kanegaye JT, Best BM, et al. Pyuria associated with acute Kawasaki disease and fever from other causes. Pediatr Infect Dis J 2009; 28:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/27\">",
"      Watanabe T, Abe Y, Sato S, et al. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007; 22:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/28\">",
"      Eladawy M, Dominguez SR, Anderson MS, Glod&eacute; MP. Abnormal liver panel in acute kawasaki disease. Pediatr Infect Dis J 2011; 30:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/29\">",
"      Dengler LD, Capparelli EV, Bastian JF, et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J 1998; 17:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/30\">",
"      Korematsu S, Uchiyama S, Miyahara H, et al. The characterization of cerebrospinal fluid and serum cytokines in patients with Kawasaki disease. Pediatr Infect Dis J 2007; 26:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/31\">",
"      Hicks RV, Melish ME. Kawasaki syndrome. Pediatr Clin North Am 1986; 33:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/32\">",
"      Salo E, Pesonen E, Viikari J. Serum cholesterol levels during and after Kawasaki disease. J Pediatr 1991; 119:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/33\">",
"      Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991; 84:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/34\">",
"      Cabana VG, Gidding SS, Getz GS, et al. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997; 42:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/35\">",
"      Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004; 46:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/36\">",
"      Centers for Disease Control. Kawasaki disease &mdash; New York. MMWR Morb Mortal Wkly Rep 1980; 29:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/37\">",
"      Uehara R, Igarashi H, Yashiro M, et al. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Gu&eacute;rin inoculation site. Pediatr Infect Dis J 2010; 29:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/38\">",
"      Sundel RP. Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 2002; 4:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/39\">",
"      Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/40\">",
"      Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/41\">",
"      Minich LL, Sleeper LA, Atz AM, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 2007; 120:e1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/42\">",
"      Yanagihara R, Todd JK. Acute febrile mucocutaneous lymph node syndrome. Am J Dis Child 1980; 134:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/43\">",
"      Barron KS. Kawasaki disease in children. Curr Opin Rheumatol 1998; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/44\">",
"      Benseler SM, McCrindle BW, Silverman ED, et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005; 116:e760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12248/abstract/45\">",
"      Jordan-Villegas A, Chang ML, Ramilo O, Mej&iacute;as A. Concomitant respiratory viral infections in children with Kawasaki disease. Pediatr Infect Dis J 2010; 29:770.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6417 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12248=[""].join("\n");
var outline_f11_61_12248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3458787\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mucositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extremity changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3460119\">",
"      Cardiovascular findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26262883\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26262954\">",
"      Delayed diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26263419\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3458787\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6417\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6417|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/1/15376\" title=\"picture 1\">",
"      Conjunctivitis in Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/34/20004\" title=\"picture 2\">",
"      Cracked red lips seen in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/2/43\" title=\"picture 3\">",
"      Strawberry tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/12/25793\" title=\"picture 4\">",
"      Edema of hands in Kawasaki disease - acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/29/5587\" title=\"picture 5\">",
"      Periungual desquamation in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6417|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/48/3851\" title=\"table 1\">",
"      Dx criteria KD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/34/5679\" title=\"table 2\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/10/6317\" title=\"table 3\">",
"      Differential Kawasaki disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3944?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=related_link\">",
"      Incomplete (atypical) Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16183?source=related_link\">",
"      Kawasaki disease: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/8/3201?source=related_link\">",
"      Patient information: Kawasaki disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_61_12249="Dementia and delirium in HIV-infected patients";
var content_f11_61_12249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dementia and delirium in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Alexander W Thompson, MD, MBA, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Andrew A Pieper, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Glenn J Treisman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12249/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12249/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/61/12249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in memory, mood, attention, and motor skills are common in HIV-infected patients and present a diagnostic challenge to the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/1\">",
"     1",
"    </a>",
"    ]. Since these symptoms can represent a wide variety of disorders, accurate diagnosis is critical for patient treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive decline in HIV infection is related to the CD4+ T-cell count nadir and duration of immunosuppression. Cognitive decline can occur in patients with a prior AIDS diagnosis despite subsequent viral suppression on ART. In one cohort study, 39 percent of patients had at least mild impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/3\">",
"     3",
"    </a>",
"    ]. By contrast, preserved cognitive functioning over time has been observed in asymptomatic HIV-infected men with strong premorbid functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and patient management of minor cognitive-motor disorder (MCMD), HIV-associated dementia complex (HAD), and",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    related delirium will be discussed here. An overview of the range of neuropsychiatric conditions associated with HIV infection and more detailed reviews of other specific conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5831?source=see_link\">",
"     \"Overview of the neuropsychiatric aspects of HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12504?source=see_link\">",
"     \"Depression, mania, and schizophrenia in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2551?source=see_link\">",
"     \"Substance abuse and addiction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1991, the American Academy of Neurology defined two levels of neurologic impairment in patients with HIV: HIV-associated dementia (HAD) and minor cognitive motor disorder (MCMD). A core difference between the two is the degree of functional impairment present; patients with HAD have more impairment than those with MCMD.",
"   </p>",
"   <p>",
"    Due to overlap in symptoms and a lack of specificity regarding the degree of neurologic impairment necessary to make these diagnoses, a new classification system has been proposed by the HIV Neurobehavioral Research Center at UCSD. The proposed system recognizes three conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic neurocognitive impairment (ANI)",
"     </li>",
"     <li>",
"      HIV-associated mild neurocognitive disorder (MND)",
"     </li>",
"     <li>",
"      HIV-associated dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Briefly, ANI refers to individuals who score one standard deviation below the mean on at least two areas of a standardized neuropsychological test; however, that impairment on testing is not causing an observable functional impairment.",
"   </p>",
"   <p>",
"    MND describes an individual who demonstrates impairment on neuropsychological testing as just described for ANI but also demonstrates some type of mild impairment in daily functioning. This description is quite close to the description for MCMD.",
"   </p>",
"   <p>",
"    HIV-associated dementia (HAD), in this classification scheme, refers to a person showing marked impairment on neuropsychological testing and in daily functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/5\">",
"     5",
"    </a>",
"    ]. The following discussion will address MCMD and HAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MINOR COGNITIVE-MOTOR DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor cognitive-motor disorder (MCMD), also referred to as HIV-1-associated minor",
"    <span class=\"nowrap\">",
"     cognitive/motor",
"    </span>",
"    disorder, describes patients with HIV who demonstrate mild cognitive, motor, or behavioral problems but lack serious impairment in daily functioning. MCMD is diagnosed by identifying at least two of the following symptoms that are not attributed to HIV-associated dementia or myelopathy: impaired attention or coordination, mental slowing, impaired memory, slowed movements, or incoordination [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence of MCMD has been estimated at 20 to 30 percent in patients with HIV who have no specific neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with MCMD present with clear and subtle neurocognitive changes that may be missed without formal neuropsychological testing. Whether MCMD predisposes to, or is an early manifestation of HIV-associated dementia, is debated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/8\">",
"     8",
"    </a>",
"    ]; some patients continue to have only minor problems while others progress to full dementia.",
"   </p>",
"   <p>",
"    Amelioration of CNS infection through ART does not guarantee reversal of MCMD. For example, in an observational study of 433 HIV-infected patients who had immune system reconstitution as a result of effective antiretroviral therapy, 27 percent of subjects had neuropsychological impairment on formal testing, a rate approximately twice that expected in normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HIV-ASSOCIATED DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated dementia (HAD) is defined by the American Academy of Neurology AIDS Task Force as a combination of acquired limitations in cognitive abilities (attention or concentration, processing speed, abstraction, memory, speech, or visual-spatial skills) plus abnormalities in motor function or changes in emotional or behavioral functioning. The patient has a clear level of consciousness, but the overall symptoms cause significant impairment in work or activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/6\">",
"     6",
"    </a>",
"    ]. AIDS dementia complex (ADC), a term used less frequently now, describes the syndrome as a subcortical dementia with changes in memory, movement (motor) and mood. A six level staging system is used to describe the severity of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/10\">",
"     10",
"    </a>",
"    ]. We will use the HAD classification.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been changes in the epidemiology of HAD since the introduction of highly active antiretroviral therapy (HAART). The incidence of HAD has declined from approximately 20 to 30 percent down to 10 to 15 percent of those with advanced HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Data from 15,380 HIV-infected patients followed in the CASCADE cohort (Concerted Action on Seroconversion to AIDS and Death in Europe) showed a decrease in the incidence of HAD from 6.49 per 1000 person-years in the pre-HAART era to 0.66 per 1000 person-years by 2003 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the overall prevalence has remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. HAD also accounts for an increasing proportion of AIDS-defining diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the post-HAART era, the following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of new HAD cases occurring in patients with higher ranges of CD4 counts (200 to 350 cells) may be increasing [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive dysfunction can be detected among patients with long-standing viral suppression on ART [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The type of \"neuropsychological impairment\" is changing. One study demonstrated an improvement in attention, verbal fluency, and visuoconstruction defects, but a deterioration in learning efficiency and complex attention [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/3\">",
"       3",
"      </a>",
"      ]. This observation was true even in patients with viral suppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This supports growing evidence that HAART does not prevent neuropsychological impairment but may alter the type of impairment experienced and delay the onset of dementia. Two studies suggest that the initiation of HAART has little impact on established neuropsychologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], particularly if immunosuppression is sustained despite treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/21\">",
"     21",
"    </a>",
"    ]. It is not clear if this observation is due to non-reversible neuronal damage, poor penetration of antiretroviral therapy into the CNS, or lack of adherence due to neurologic impairment.",
"   </p>",
"   <p>",
"    In the past, there was little attention to the contribution of age-related neurodegenerative diseases to cognitive impairment in HIV, because the infection existed almost exclusively among younger individuals. However, the long-term survival of HIV-infected patients now routinely extends into older age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/22\">",
"     22",
"    </a>",
"    ]. The number of HIV-infected patients &gt;65 years of age has increased from approximately 1000 to &gt;10,000 in the past decade alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/23\">",
"     23",
"    </a>",
"    ]; furthermore it is predicted that 50 percent of nationally prevalent AIDS cases will fall into this older age group by the year 2015 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=see_link\">",
"     \"HIV and the older patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV disseminates to the central nervous system (CNS) soon after primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/9\">",
"     9",
"    </a>",
"    ]. It has been proposed that HIV enters the CNS via infected monocytes that traverse the blood brain barrier to replenish perivascular macrophages. Brain macrophages and microglial are thought to be the key cells that are infected with HIV and likely to be involved in the pathogenesis of HAD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/11\">",
"     11",
"    </a>",
"    ]. There is little evidence that HIV infects astrocytes, neurons, or oligodendrocytes.",
"   </p>",
"   <p>",
"    Leading theories of the pathologic mechanisms of neuronal damage in HIV-associated dementia involve activation of macrophages or microglial cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activation of cytokines and chemokines, leading to abnormal neuronal pruning [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/15\">",
"     15",
"    </a>",
"    ]. Autopsy studies of demented AIDS patients show characteristic white matter changes and demyelinization, microglial nodules, multinucleated giant cells, and perivascular infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Basal ganglia and nigrostriatal structures are affected early in the course of the dementia, with subsequent diffuse neuronal loss resulting in up to 40 percent reduction in frontal and temporal neurons. Genetic sequencing of envelope proteins from neurotropic strains of HIV suggests that a particular viral variant, which more efficiently infects tissue macrophages and microglia, is associated with HAD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/27\">",
"     27",
"    </a>",
"    ]. Although ART reduces HIV RNA in cerebrospinal fluid, a significant proportion of patients continue to show signs of",
"    <span class=\"nowrap\">",
"     macrophage/microglia",
"    </span>",
"    activation even after years of durable viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/28\">",
"     28",
"    </a>",
"    ]. At present, the pathophysiologic mechanisms that drive this persistent inflammatory response are unknown. However, one study suggested a possible role for osteopontin, an extracellular protein involved in immune cell activation; levels of osteopontin were increased in HIV-infected patients with HAD compared to HIV patients without neurologic deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV may inhibit neural progenitor cell proliferation through an interaction with the chemokine receptors CCR3 and CXCR4 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/30\">",
"     30",
"    </a>",
"    ]. However, it is unclear whether this is important in the pathogenesis of AIDS dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another cofactor that may contribute to neuropathogenesis in HIV-infected patients is hepatitis C virus (HCV) infection. HCV sequences have been detected in cerebrospinal fluid and brain tissue; virus may traffic into the CNS via macrophages, which infect microglia and astrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. In one autopsy study of 25 HIV-infected patients with a history of neurologic impairment, nonstructural and core HCV antigens were demonstrated in brain homogenates by immunoblot analysis in 11 of 12",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/37\">",
"     37",
"    </a>",
"    ]. HCV core protein may cause neuronal damage through the production of proinflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the CASCADE cohort noted above, 222 patients developed HAD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/13\">",
"     13",
"    </a>",
"    ]. Risk factors included lower CD4 cell counts, older age at seroconversion, duration of HIV infection, and the presence of a prior AIDS-defining diagnosis.",
"   </p>",
"   <p>",
"    In the pre-HAART era, CSF HIV RNA levels correlated with the extent of HIV-associated dementia and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The correlation of HIV RNA levels and risk of HAD is not as clear in the post-HAART era as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma and CSF HIV RNA levels were prospectively evaluated as predictors of HIV-associated dementia in 203 patients with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &lt;200/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/42\">",
"       42",
"      </a>",
"      ]. After a median follow-up of 21 months, 74 patients (36 percent) developed HIV-associated dementia. Neither plasma nor CSF HIV RNA levels were associated with dementia, suggesting that lower HIV RNA levels attained with HAART diminished the utility of the degree of viremia as a risk factor. This study did not evaluate issues of viral resistance, medication adherence, or changes in antiretroviral medications, which may have occurred after the baseline visit.",
"     </li>",
"     <li>",
"      In one study of 146 non-demented patients followed over a 30-month time period, 45 subsequently met criteria for incident HAD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/8\">",
"       8",
"      </a>",
"      ]. In a multivariate analysis, the presence of depression or MCMD at baseline were significant risk factors for this outcome.",
"     </li>",
"     <li>",
"      Impairments in psychomotor speed testing one to two years prior to death, or at the time of AIDS diagnosis in 100 patients, predicted development of HAD; these results are consistent with the observation that MCMD may be a precursor to HAD [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Minor cognitive-motor disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HIV-infected patients who are able to control plasma viremia without medications (ie, \"elite controllers\") do not have evidence of intrathecal HIV RNA production nor evidence of CSF inflammation; thus they appear to be at limited risk for the development of HAD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAD typically presents with the classic triad of symptoms of subcortical dementia: memory and psychomotor speed impairment, depressive symptoms and movement disorders. The absence of higher cortical dysfunction including aphasia, agnosia, and apraxia help distinguish HAD from classical \"cortical\" dementia, such as Alzheimer disease. However, the distinction between cortical and subcortical dementias is blurred as a patient with late and severe HIV dementia may have dysfunction in both language and praxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Early symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the onset, patients usually experience subtle symptoms that may be overlooked or attributed to fatigue or other illness, such as slight difficulty with reading, comprehension, memory, and mathematical skills. Early motor symptoms include unsteady gait, leg weakness, and tremor. Other early manifestations may include apathy, lethargy, loss of sexual drive, and diminished emotional responsiveness. Early language deficits are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affective disturbance is frequently associated with HIV dementia and may be an early manifestation of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/8\">",
"     8",
"    </a>",
"    ]. These patients frequently display typical depressive symptoms of anhedonia, irritable mood, sleeplessness, weight loss, restlessness and anxiety. Unlike other individuals with major depression, these patients are frequently distinguished by lack of crying spells or reported sadness. Depression with HIV-associated dementia may progress to psychosis with paranoid ideas and hallucinations. Furthermore, approximately 5 to 8 percent of patients with HIV-associated dementia develop AIDS mania. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12504?source=see_link\">",
"     \"Depression, mania, and schizophrenia in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Later symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In its advanced form, HIV dementia presents with features of a frontal subcortical dementing process in association with severe immunodeficiency. Declines in mental alacrity (bradyphrenia) and slowness of movement (bradykinesia) are prominent features and the patient often complains of memory difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, patients experience impaired saccadic eye movements, marked difficulty with smooth limb movement (especially in the lower extremities), dysdiadochokinesia, hyperreflexia, and frontal release signs such as grasp, root, snout, and glabellar reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive neuropsychological testing helps to determine the extent of the cognitive impairment and identifies other potential contributing factors, such as depression and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/14\">",
"     14",
"    </a>",
"    ]. However, such extensive testing is costly and requires highly skilled professionals for administration and interpretation. This problem has promoted the development of bedside screening tools.",
"   </p>",
"   <p>",
"    Two proposed screening tests focus on tasks that would be affected by frontal or subcortical disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Further validation studies of these screening tools will be needed since both lack high specificity and therefore risk misclassification of patients. The modified HIV Dementia Scale may also be a useful bedside screen that can be administered serially to document disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain imaging usually demonstrates cortical atrophy; imaging is also needed to eliminate other potential diagnoses associated with poor cognition. Studies are being performed to determine if other modalities, such as magnetic resonance imaging, may have a role in the diagnosis of neurocognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive impairment may be a presenting symptom of other opportunistic infections, such as toxoplasma encephalitis, progressive multifocal leukoencephalopathy, or other conditions and infections (eg, tertiary syphilis, nutritional deficiencies, or thyroid dysfunction). The diagnostic evaluation in tertiary syphilis would also require lumbar puncture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment for HIV-associated dementia is an optimal HAART regimen combined with aggressive treatment of associated psychiatric problems (such as mood, anxiety, or substance use disorders).",
"   </p>",
"   <p>",
"    The AIDS Clinical Trials Group is investigating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    , which is used for the treatment of Parkinson disease, for its potential efficacy in treating dementia. ACTG 5090 is a 48-week phase II, double blind, placebo-controlled study of the Selegiline Transdermal System (STS) in HIV-infected subjects experiencing cognitive impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiretroviral medications differ in their ability to penetrate the CNS, which may have implications for drug resistance and clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CNS penetration &mdash; Drugs with the highest levels of CSF penetration include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      , stavudine, lamivudine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      , and lopinavir with ritonavir boosting [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. Some data demonstrate that regimens with good CNS penetration lead to better HIV RNA suppression in the cerebrospinal fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/52\">",
"       52",
"      </a>",
"      ]. However, there are conflicting results as to whether better drug penetration is associated with neurologic improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/52,57,58\">",
"       52,57,58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Whether CSF levels correlate with brain parenchymal levels is not known and there are few data are available on brain pathology in patients with HIV-related dementia. One study evaluated 374 brains from patients with AIDS who had available ART histories [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/59\">",
"       59",
"      </a>",
"      ]. The 76 patients who had documented HIV-related brain pathology did not differ from the rest of the study patients in duration of infection, gender,",
"      <span class=\"nowrap\">",
"       race/ethnicity,",
"      </span>",
"      or mode of transmission. The risk of HIV-related brain pathology in patients on NNRTI-based ART was approximately half that of those who took either PI-based ART or no ART at all.",
"     </li>",
"     <li>",
"      Issues of drug resistance &mdash; The blood-brain barrier and the low levels of CSF drug concentrations that have been documented raise concerns regarding the evolution of drug resistance in the CNS compartment. One study of 63 HIV-infected patients demonstrated that in 18 of 40 patients, for whom virtual phenotype resistance data were available, there was a fold-change of resistance between the CSF and plasma virus for at least one drug in the combination regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other more encouraging data suggest that issues of compartmentalized infection and the limited tissue penetration of ART may be less important than therapy itself [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/60\">",
"     60",
"    </a>",
"    ]. A cross-sectional analysis was performed of 139 HIV-infected patients categorized as having either therapeutic success or virologic failure based on plasma HIV RNA levels on ART; a third group were untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/61\">",
"     61",
"    </a>",
"    ]. HIV RNA suppression in the CSF occurred in 72 percent of subjects with therapeutic success. However, even in the group with virologic failure, CSF HIV RNA levels were significantly lower than in the untreated HIV subgroup. This favorable outcome, despite the presence of drug resistance, may be related to reduced T cell activation and trafficking.",
"   </p>",
"   <p>",
"    Attempts have been made to establish a CNS penetration effectiveness (CPE) rank of various ART regimens based on chemical properties of the drugs, data on CSF concentrations, and ART effectiveness in various clinical studies of neurocognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/62\">",
"     62",
"    </a>",
"    ]. Although a cross-sectional analysis of 467 patients taking ART suggested that a low CPE score was associated with isolating HIV RNA in the CSF compartment, CPE ranks explained only 12 percent of the variance in viral loads. This analysis was limited by heterogeneity among the studies in their assessment of clinical outcomes and lack of data on specific drugs and CNS penetrance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Psychotropic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with depressive symptoms should undergo a complete psychiatric evaluation to determine the need for antidepressant medications. If antidepressants are initiated, the patient should be carefully monitored for the emergence of mania.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    (Ritalin) or other stimulants are often effective treatments for apathy. As with all cases of dementia, safety assessments should be used and patients in need of supervision should be referred to appropriate facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Memantine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     Memantine",
"    </a>",
"    is an analog of the antiviral drug amantadine and acts as an antagonist of the N-methyl-D-aspartate (NMDA) receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/63\">",
"     63",
"    </a>",
"    ]. It has been used for the treatment of neurodegenerative diseases, such as Alzheimer disease. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     \"Memantine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized double-blind placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    for the treatment of AIDS dementia complex was performed in 140 HIV-infected patients with mild to severe cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/63\">",
"     63",
"    </a>",
"    ]. All patients were treated for 16 weeks followed by a four-week washout period and re-evaluation at week 20. Although therapy was well tolerated, there were no significant differences in cognitive performance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DELIRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is the development of a disturbance of consciousness with a reduced ability to sustain, focus, or shift attention, occurring over a short period of time. It is the result of global derangement of cerebral function, and is also referred to as encephalopathy. The presence of a disturbance in consciousness is a key factor in distinguishing delirium from MCMD and HAD, where the patient has a clear level of consciousness.",
"   </p>",
"   <p>",
"    Delirium is characterized by a waxing and waning course; patients may appear fine during one exam and grossly impaired a short time later. The level of consciousness may vary from hyperalert to stuporous. Delirium is characterized by a change in cognition or perceptual disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/64\">",
"     64",
"    </a>",
"    ]. Delirium may also be associated with changes in the sleep wake cycle, psychomotor activity (hypo or hyperactive), and emotional state [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medically compromised patients such as those with advanced HIV disease are more likely to develop delirium. Seriously ill patients may also develop delirium from sensory deprivation (such as &ldquo;ICU psychosis&rdquo;) or minor complications such as a urinary tract infection.",
"   </p>",
"   <p>",
"    The importance of recognizing and treating the underlying cause of a delirium cannot be overstated. In one study of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients admitted to a teaching hospital, the diagnosis of delirium was associated with increased mortality, longer stays, and greater care needs upon discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/66\">",
"     66",
"    </a>",
"    ]. Another study of 41 patients admitted to a skilled nursing facility also found that delirium was a marker for decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/67\">",
"     67",
"    </a>",
"    ]. Unfortunately, delirium still remains an underdiagnosed condition in almost all populations of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical etiology of delirium should be aggressively sought through careful history and physical examination, laboratory tests, electrocardiogram, electroencephalogram (EEG), radiologic examinations and critical review of all medications. While an EEG may help guide diagnosis, it is nonspecific and usually not required. Common etiologies of delirium include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intoxication by drugs and poisons",
"     </li>",
"     <li>",
"      Withdrawal syndromes",
"     </li>",
"     <li>",
"      Metabolic encephalopathies (endocrine,",
"      <span class=\"nowrap\">",
"       fluid/electrolyte,",
"      </span>",
"      and organ problems)",
"     </li>",
"     <li>",
"      Infections (intracranial or systemic)",
"     </li>",
"     <li>",
"      Neoplasia",
"     </li>",
"     <li>",
"      Head trauma and space-occupying lesions",
"     </li>",
"     <li>",
"      Epilepsy",
"     </li>",
"     <li>",
"      Vascular disorders (cardio and cerebrovascular)",
"     </li>",
"     <li>",
"      Hypersensitivity reactions",
"     </li>",
"     <li>",
"      Physical agents (temperature, radiations, and electricity)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a mental status change that might mimic delirium in the HIV-infected patient includes AIDS mania, major depression, bipolar disorder, panic disorder, and schizophrenia. Delirium can usually be distinguished by its rapid onset, fluctuating level of consciousness, a waxing and waning course, and link to a medical etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12504?source=see_link\">",
"     \"Depression, mania, and schizophrenia in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious etiologies that should be considered include cytomegalovirus encephalitis, progressive multifocal leukoencephalopathy, cerebral toxoplasmosis, cryptococcal meningitis, and CNS lymphoma. (See appropriate topic cards).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of life-threatening causes of delirium such as delirium tremens, a hyperactive form of delirium that can result from the withdrawal of sedative-hypnotic medications (alcohol, benzodiazepines, and barbiturates).",
"   </p>",
"   <p>",
"    General issues in the treatment of delirium include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Orienting the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient is diagnosed with a delirium, close and often constant observation is essential. This increased level of observation provides safety and reassurance to the patient. It also provides information to clinicians and may limit the use of more restrictive measures, like restraints. Providing a stable environment can include a private room, clock, calendar, and board that indicates location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Controlling the symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotic behavior is managed effectively through low doses of neuroleptic agents, both typical and atypical. First generation (or typical) neuroleptics, such as haloperidol, are widely used, but may cause extrapyramidal motor symptoms and akathisia. Second generation (atypical) neuroleptics are often favored because of decreased liability to motor side effects, but have other metabolic consequences. Sedating drugs, such as benzodiazepines, are widely used but often worsen delirium and complicate diagnosis, and are probably better avoided unless they are treating the underlying cause of the delirium. One randomized controlled trial compared the use of chlorpromazine, haloperidol, and lorazepam in the treatment of delirium in AIDS patients. This study found that low doses of haloperidol and chlorpromazine were both effective while lorazepam use caused side effects resulting in the termination of that arm of the study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12249/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Identifying and correcting the cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough investigation should be initiated to address the potential medical etiologies. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These aspects of management of the patient with delirium are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24104124\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor cognitive-motor disorder (MCMD), also referred to as HIV-1-associated minor",
"      <span class=\"nowrap\">",
"       cognitive/motor",
"      </span>",
"      disorder, describes patients with HIV who demonstrate mild cognitive, motor, or behavioral problems, but lack serious impairment in daily functioning. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Minor cognitive-motor disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-associated dementia (HAD) is defined as a combination of cognitive dysfunction plus abnormalities in motor function or changes in emotional or behavioral functioning. The patient has a clear level of consciousness, but the overall symptoms cause significant impairment in work or activities of daily living (See",
"      <a class=\"local\" href=\"#H4\">",
"       'HIV-associated dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain macrophages and microglial are the key cells that are infected with HIV and likely to be involved in the pathogenesis of HIV associated dementia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-associated dementia typically presents with the classic symptoms of subcortical dementia: memory and psychomotor impairment, depressive symptoms, and movement disorders. The absence of higher cortical dysfunction helps to distinguish HIV associated dementia from classical \"cortical\" dementia, such as Alzheimer disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comprehensive neuropsychological testing helps to determine the extent of the cognitive impairment and identifies other potential contributing factors, such as depression and anxiety (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard treatment for HIV-associated dementia includes potent antiretroviral therapy combined with aggressive treatment of associated psychiatric problems (such as mood, anxiety, or substance use disorders). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delirium is characterized by the rapid development of a disturbance of consciousness with a reduced ability to sustain, focus, or shift attention. The presence of a disturbance in consciousness is a key factor in distinguishing delirium from HIV associated neurocognitive impairment or HIV associated dementia, where the patient has a clear level of consciousness. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Delirium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/1\">",
"      Shapshak P, Kangueane P, Fujimura RK, et al. Editorial neuroAIDS review. AIDS 2011; 25:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/2\">",
"      Price RW. Neurological complications of HIV infection. Lancet 1996; 348:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/3\">",
"      Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/4\">",
"      Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 2007; 69:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/5\">",
"      Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/6\">",
"      Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     Cournos, F.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/8\">",
"      Stern Y, McDermott MP, Albert S, et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 2001; 58:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/9\">",
"      McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007; 21:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/10\">",
"      Sidtis JJ, Price RW. Early HIV-1 infection and the AIDS dementia complex. Neurology 1990; 40:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/11\">",
"      Gonz&aacute;lez-Scarano F, Mart&iacute;n-Garc&iacute;a J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/12\">",
"      Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 Suppl 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/13\">",
"      Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/14\">",
"      Berger JR, Brew B. An international screening tool for HIV dementia. AIDS 2005; 19:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/15\">",
"      Moroni M, Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. AIDS 2003; 17 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/16\">",
"      Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/17\">",
"      Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/18\">",
"      Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/19\">",
"      Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/20\">",
"      Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/21\">",
"      Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/22\">",
"      Valcour V, Paul R. HIV infection and dementia in older adults. Clin Infect Dis 2006; 42:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/23\">",
"      Stoff DM, Khalsa JH, Monjan A, Portegies P. Introduction: HIV/AIDS and Aging. AIDS 2004; 18 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/24\">",
"      Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/25\">",
"      Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/26\">",
"      Gray F, Chr&eacute;tien F, Vallat-Decouvelaere AV, Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/27\">",
"      Dunfee RL, Thomas ER, Gorry PR, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A 2006; 103:15160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/28\">",
"      Ed&eacute;n A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after &gt;4 years of effective highly active antiretroviral therapy. J Infect Dis 2007; 196:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/29\">",
"      Burdo TH, Ellis RJ, Fox HS. Osteopontin is increased in HIV-associated dementia. J Infect Dis 2008; 198:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/30\">",
"      Krathwohl MD, Kaiser JL. HIV-1 promotes quiescence in human neural progenitor cells. J Infect Dis 2004; 190:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/31\">",
"      Kao AW, Price RW. Chemokine receptors, neural progenitor cells, and the AIDS dementia complex. J Infect Dis 2004; 190:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/32\">",
"      Laskus T, Radkowski M, Bednarska A, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 2002; 76:10064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/33\">",
"      Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/34\">",
"      Fishman SL, Murray JM, Eng FJ, et al. Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis 2008; 197:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/35\">",
"      Laskus T, Radkowski M, Adair DM, et al. Emerging evidence of hepatitis C virus neuroinvasion. AIDS 2005; 19 Suppl 3:S140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/36\">",
"      Vivithanaporn P, Maingat F, Lin LT, et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One 2010; 5:e12856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/37\">",
"      Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/38\">",
"      Cinque P, Vago L, Ceresa D, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS 1998; 12:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/39\">",
"      Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/40\">",
"      Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997; 175:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/41\">",
"      McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/42\">",
"      Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/43\">",
"      Dunlop O, Bj&oslash;rklund R, Bruun JN, et al. Early psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitis. Acta Neurol Scand 2002; 105:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/44\">",
"      Probasco JC, Deeks SG, Lee E, et al. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS 2010; 24:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/45\">",
"      Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/46\">",
"      Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/47\">",
"      Davis HF, Skolasky RL Jr, Selnes OA, et al. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/48\">",
"      Roc AC, Ances BM, Chawla S, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol 2007; 64:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/49\">",
"      Castelo JM, Courtney MG, Melrose RJ, Stern CE. Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise. Arch Neurol 2007; 64:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/50\">",
"      Ances BM, Christensen JJ, Teshome M, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology 2010; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/51\">",
"      Sacktor N, Tarwater PM, Skolasky RL, et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001; 57:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/52\">",
"      Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/53\">",
"      Enting RH, Hoetelmans RM, Lange JM, et al. Antiretroviral drugs and the central nervous system. AIDS 1998; 12:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/54\">",
"      Foudraine NA, Hoetelmans RM, Lange JM, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/55\">",
"      Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/56\">",
"      Letendre SL, van den Brande G, Hermes A, et al. Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid. Clin Infect Dis 2007; 45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/57\">",
"      Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003; 60:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/58\">",
"      Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73:342.",
"     </a>",
"    </li>",
"    <li>",
"     Everall, I, Vada, F, Letendre, S, et al. Reducing the prevalence of priamry HIV brain pathology by antiretroviral therapy. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract #67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/60\">",
"      McArthur JC, Letendre SL. Is the glass three-quarters full or one-quarter empty? J Infect Dis 2006; 194:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/61\">",
"      Spudich S, Lollo N, Liegler T, et al. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis 2006; 194:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/62\">",
"      Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/63\">",
"      Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007; 21:1877.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Text Revision. Washington, D.C.: American Psychiatric Association, 2000.",
"    </li>",
"    <li>",
"     Slavney PR. Psychiatric Dimensions of Medical Practice. What Primary-Care Physicians Should Know about Delirium, Demoralization, Suicidal Thinking, and Competence to Refuse Medical Advice. Johns Hopkins University Press, 1998, Baltimore and London.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/66\">",
"      Uldall KK, Harris VL, Lalonde B. Outcomes associated with delirium in acutely hospitalized acquired immune deficiency syndrome patients. Compr Psychiatry 2000; 41:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/67\">",
"      Uldall KK, Ryan R, Berghuis JP, Harris VL. Association between delirium and death in AIDS patients. AIDS Patient Care STDS 2000; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12249/abstract/68\">",
"      Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3723 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-218.28.111.102-8C7B610DBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12249=[""].join("\n");
var outline_f11_61_12249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24104124\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MINOR COGNITIVE-MOTOR DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HIV-ASSOCIATED DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Early symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Later symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Psychotropic medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Memantine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DELIRIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Orienting the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Controlling the symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Identifying and correcting the cause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24104124\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12504?source=related_link\">",
"      Depression, mania, and schizophrenia in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=related_link\">",
"      HIV and the older patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=related_link\">",
"      Memantine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5831?source=related_link\">",
"      Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2551?source=related_link\">",
"      Substance abuse and addiction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_61_12250="Chronic nonallergic rhinitis";
var content_f11_61_12250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic nonallergic rhinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12250/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12250/contributors\">",
"     Phillip L Lieberman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12250/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/61/12250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/61/12250/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/61/12250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic nonallergic rhinitis is not a specific disease, but rather a syndrome diagnosed by excluding other disorders. The lack of clarity regarding the pathogenesis of this condition has led to an imprecise terminology and a number of synonyms used to refer to this entity. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vasomotor rhinitis",
"     </li>",
"     <li>",
"      Idiopathic rhinitis",
"     </li>",
"     <li>",
"      Nonallergic-noninfectious rhinitis",
"     </li>",
"     <li>",
"      Intrinsic rhinitis",
"     </li>",
"     <li>",
"      Nonallergic vasomotor rhinitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis, incidence, clinical manifestations, diagnosis, and treatment of chronic nonallergic rhinitis are presented in this topic review. Allergic rhinitis and an overview of other forms of rhinitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonallergic rhinitis (NAR) is best defined by the chronic presence of one or more of the four following cardinal symptoms of rhinitis, in the absence of a specific etiology (such as an immunologic, infectious, pharmacologic, structural, hormonal, vasculitic, metabolic, or atrophic cause):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sneezing",
"     </li>",
"     <li>",
"      Rhinorrhea",
"     </li>",
"     <li>",
"      Nasal congestion",
"     </li>",
"     <li>",
"      Postnasal drainage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is no consensus about how long symptoms should be present to establish chronicity, some studies have utilized a minimum duration of over one year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single unifying theory of pathogenesis for chronic NAR, and it may represent a group of incompletely-defined disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, NAR can be broadly divided into noninflammatory and inflammatory forms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/6-33\">",
"     6-33",
"    </a>",
"    ], with the inflammatory form being further divided into cases that are either eosinophilic or non-eosinophilic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/1,2,6-33\">",
"     1,2,6-33",
"    </a>",
"    ]. With all forms of chronic nonallergic rhinitis, there is also a variable component of autonomic dysregulation. In the noninflammatory form, these neurologic abnormalities are the only demonstrable findings.",
"   </p>",
"   <p>",
"    Patients with NAR often exhibit a clinical hypersensitivity to odors, which is usually manifested by the production of rhinitis symptoms. One group of researchers evaluated the neurogenic responses to",
"    <span class=\"nowrap\">",
"     chemical/olfactory",
"    </span>",
"    stimuli in patients with NAR using functional magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/34\">",
"     34",
"    </a>",
"    ]. Subjects underwent MRI during exposure to different types of odors. They exhibited increased blood flow to several odor-sensitive regions of the brain in response to both pleasant (vanilla) and unpleasant (hickory smoke) odors. The neurologic responses were associated with the production of symptoms upon exposure to hickory smoke. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Noninflammatory",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the noninflammatory form (as defined by biopsies negative for inflammation), it has been postulated that the disease results from an abnormality in the autonomic nervous system, including the adrenergic, cholinergic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonadrenergic, noncholinergic (NANC) innervation of the nose [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. However, such abnormalities have also been demonstrated in some inflammatory cases, and in this context, have been proposed to be secondary to a primary inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/6,7,11,28\">",
"     6,7,11,28",
"    </a>",
"    ]. Thus, the pathogenic role of these abnormalities is unclear.",
"   </p>",
"   <p>",
"    Gustatory rhinitis is a term applied to the development of profuse, watery rhinorrhea or congestion in association with eating hot or spicy foods [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/35\">",
"     35",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Prominent rhinorrhea without other symptoms'",
"    </a>",
"    below). It is most likely a subtype of noninflammatory, nonallergic rhinitis.",
"   </p>",
"   <p>",
"    Patients with noninflammatory, nonallergic rhinitis may display the following abnormal neurologic findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal responses to various neurogenic stimulation, including heightened responses (in the form of rhinitis symptoms) to histamine, cold stimulation of the extremities and nasal mucosa,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      , and other stimuli designed to activate cholinergic responses [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/6,9,28\">",
"       6,9,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diminished responses to vasoconstrictive stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased concentrations of intranasal neuropeptides, such as VIP and substance P [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these neural processes, nasal secretory abnormalities may also be important to the pathogenesis of NAR. In one study, subjects with allergic rhinitis secreted higher amounts of albumin and an unidentified 26 kilo-Dalton protein than did those with NAR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/37\">",
"     37",
"    </a>",
"    ]. Since production of the latter protein could be stimulated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    , it was thought to occur in secretory mucosal glands. This implies that there is a qualitative difference in the glandular mucosa, which may distinguish patients with allergic from those with NAR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inflammatory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonallergic rhinitis with nasal eosinophilia syndrome (NARES) is the most common type of inflammatory NAR. The clear nasal secretions in these patients contain greater than 25 percent eosinophils. Nasal biopsies from these patients commonly show increased eosinophils, as well as increased numbers of mast cells and prominent mast cell degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. The presence of eosinophils in nasal secretions can be assessed in the office by having the patient blow the nose into a piece of &ldquo;wax paper&rdquo; and applying the secretions onto a glass slide. Once dried, the secretions are stained with Wright&rsquo;s stain and examined under a light microscope. Although not considered essential for the diagnosis, the author has performed this examination for years and has found that a high eosinophil count usually predicts a good response to intranasal glucocorticoids.",
"   </p>",
"   <p>",
"    The cellular inflammatory infiltrate may have dominant cells other than eosinophils. Nasal cytology in some cases shows a predominance of mast cells and neutrophils as well [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. These histologic findings may be associated with different clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/38\">",
"     38",
"    </a>",
"    ]. As noted above, the presence of eosinophilia can indicate responsiveness to glucocorticoids. It may also be associated with a higher incidence of asthma and more severe symptoms than when the predominant pattern is characterized by neutrophilia. When mast cells are the predominant cell type, nasal itching is often a characteristic feature [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Evidence for a localized allergic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic NAR have negative skin and in vitro tests for allergen-specific IgE, by definition, and thus lack evidence of increased systemic production of IgE. However, IgE production may occur locally in the nasal tissue in patients with negative skin tests, as well as in patients with typical allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/2,40-43\">",
"     2,40-43",
"    </a>",
"    ]. This phenomenon of local production was also demonstrated in two ex vivo studies in which there was production of allergen specific IgE in nasal explants from patients with rhinitis who had negative skin tests and serum RAST tests [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Increased numbers of high affinity receptors for IgE have been found in nasal mucosal tissues of some patients with chronic NAR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/2\">",
"     2",
"    </a>",
"    ]. In keeping with this theory of local IgE-mediated allergy, one group has shown that as many as one-half of patients with chronic NAR react to nasal challenge with allergen, especially dust mite allergen, with symptoms and signs similar to those in patients with typical allergic rhinitis and significantly different from controls without rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/41,46,47\">",
"     41,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, other researchers (using similar techniques) were unable to demonstrate consistent responses to nasal allergen challenge in patients with NAR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/48\">",
"     48",
"    </a>",
"    ]. These findings challenge the concept that NAR results from a localized, IgE-mediated mechanism. Non-specific hyperreactivity of the nasal mucosa due to inflammation from another etiology could be an alternative explanation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhinitis, in both its allergic and nonallergic forms, affects 10 to 40 percent of the population in industrialized countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/49\">",
"     49",
"    </a>",
"    ]. Pure chronic NAR may be responsible for anywhere from 17 to 52 percent of all cases of rhinitis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/3,50-57\">",
"     3,50-57",
"    </a>",
"    ]. The prevalence of NAR in children is less well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Much of the data utilized to establish the prevalence of chronic NAR have been gathered from allergy specialty practices, although there have been some community-based epidemiologic surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/50-54,62,63\">",
"     50-54,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of pure NAR underestimates the impact of this condition since it coexists with allergic rhinitis in a substantial subset of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with both conditions have been described as having \"mixed\" rhinitis, although they are generally classified as allergic, since there is no established United States diagnostic code for \"mixed\" allergic and nonallergic disease.",
"   </p>",
"   <p>",
"    In addition, in the presence of allergen-specific IgE, it is difficult to establish the existence of concomitant NAR. The Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology has estimated that, taking this underestimation into account, approximately 50 percent of patients presenting with rhinitis may have the nonallergic form (alone or as mixed disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/55\">",
"     55",
"    </a>",
"    ]. Based upon a survey of American allergists, 34 percent of 975 rhinitis patients were identified as having the \"mixed\" form of rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/54\">",
"     54",
"    </a>",
"    ]. Extrapolating these data to the overall incidence of rhinitis in the United States revealed that NAR may affect as many as 17 million Americans and that an additional 22 million may suffer from the \"mixed form\" of rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1685189\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAR presents later in life than allergic rhinitis, with 70 percent of patients presenting after 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/53,64\">",
"     53,64",
"    </a>",
"    ]. In comparison, the onset of allergic rhinitis usually occurs before age 20 (and often in childhood).",
"   </p>",
"   <p>",
"    Women make up the majority of patients in most studies, so there may be a female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/51,65\">",
"     51,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rhinitis of the elderly (also called senile rhinitis) is a term used to describe NAR in older adults. It is characterized by prominent rhinorrhea and aggravated by eating and environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Prominent rhinorrhea without other symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history is the",
"    <strong>",
"     most",
"    </strong>",
"    <strong>",
"     important",
"    </strong>",
"    tool used to make the distinction between NAR and other forms of rhinitis.",
"   </p>",
"   <p>",
"    Compared with allergic rhinitis, features that are helpful in correctly identifying nonallergic disease include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent and prominent clinical manifestations are nasal blockage and postnasal drip [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/67\">",
"       67",
"      </a>",
"      ]. In contrast, patients with allergic rhinitis report prominent eye symptoms, sneezing, and rhinorrhea.",
"     </li>",
"     <li>",
"      Patients with NAR often cannot readily identify triggers, such as times of year when specific pollens are prevalent, or exposure to animals. In contrast, most patients with allergic rhinitis can identify one or more triggers.",
"     </li>",
"     <li>",
"      Symptoms most commonly occur throughout the year (eg, perennial), although the condition may be exacerbated by weather conditions, particularly during the spring and fall [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/68\">",
"       68",
"      </a>",
"      ]. Symptoms in those with allergic disease usually show seasonal patterns, although some have perennial symptoms.",
"     </li>",
"     <li>",
"      Patients with NAR are less likely to have asthma and other allergic disorders or a family history of allergic disorders. In one series, 108 consecutive patients referred to an allergy clinic for chronic rhinitis were categorized as having NAR, allergic rhinitis (AR), or chronic rhinosinusitis (CRS) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/69\">",
"       69",
"      </a>",
"      ]. Among those with NAR, 9 percent had concomitant asthma, whereas asthma was present in 33 and 42 percent of patients with AR and CRS, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1685104\">",
"    <span class=\"h2\">",
"     Characteristic triggers",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory irritants (eg, cigarette smoking, strong scents, and fragrances) are prominent inducers of symptoms, although this may be true for patients with longstanding allergic rhinitis also. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link&amp;anchor=H7950557#H7950557\">",
"       \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\", section on 'Increasing sensitivity over time'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weather changes (eg, fluctuations in temperature, humidity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      barometric pressure) affect many patients with NAR. In a study using a unique environmental exposure chamber designed to simulate weather conditions in a controlled setting, 37 subjects were challenged with cold, dry air and temperature changes [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/70\">",
"       70",
"      </a>",
"      ]. Nasal patency was assessed with acoustic rhinometry and rhinorrhea, by measurement of nasal secretions. In addition, subjective measures of nasal symptoms were also evaluated. Significant symptoms with objective confirmation were induced in response to these simulated weather changes.",
"     </li>",
"     <li>",
"      Heated or spicy foods induce watery rhinorrhea in patients with the syndrome of gustatory rhinitis, which can be considered a subtype of NAR. Food triggers are more common in older adults, and gustatory rhinitis and rhinitis of the elderly overlap [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prominent rhinorrhea without other symptoms'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasal turbinates can appear boggy and edematous in both allergic and NAR. The mucosal tissue is more often erythematous in nonallergic disease, as compared to the pale bluish hue or pallor seen with allergic rhinitis. However, none of these findings is diagnostic, and the mucosa can even appear relatively normal, particularly in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of chronic NAR is based on a characteristic history and physical examination, combined with the absence of evidence for clinical allergy to aeroallergens. It is therefore a diagnosis of exclusion. However, in practical terms, allergy testing is not essential to making a presumptive initial diagnosis of NAR and beginning therapy. In addition, allergic and nonallergic rhinitis can coexist, and in such cases, it may only become clear that the patient has both disorders in retrospect, once an effective combination of medications is found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4107301\">",
"    <span class=\"h2\">",
"     Referral for allergy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not necessary to perform allergy testing before making a presumptive diagnosis of NAR and initiating treatment, as previously mentioned. However, if the patient is not experiencing adequate improvement, then testing for allergy is indicated to clarify the etiology.",
"   </p>",
"   <p>",
"    Allergy testing can be accomplished either through skin testing or with blood tests. In general, skin testing with aeroallergens is the more sensitive and specific of the two methods, but it should only be performed by an allergy expert and thus referral is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other method of identifying allergic sensitivities is immunoassays to detect allergen-specific IgE antibodies in the serum. These tests are widely available and require no patient preparation (such as discontinuation of medications). IgE immunoassays provide similar information as that obtained with allergen skin tests, although they are variably more expensive and less sensitive for the diagnosis of allergy to inhalant allergens, compared with skin tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of in vitro allergy tests\", section on 'Accuracy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In evaluating patients for allergy, clinicians should be mindful that a positive skin test for allergy or a positive in vitro test, by itself, does not prove that the patient is allergic to that substance. The result must be consistent with the clinical history, with symptoms occurring during the appropriate season, or upon exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of limited panels of IgE immunoassays in the primary care setting has been evaluated in the diagnosis and management of rhinitis. Such testing can improve diagnostic accuracy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    management when skin testing is not easily obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. These panels typically test for IgE antibodies to common seasonal and perennial allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/72,74\">",
"     72,74",
"    </a>",
"    ]. Some perennial allergens are relevant to almost all populations (eg, dust mites, animal danders). However, other allergens (pollens and molds) are relevant to specific geographic areas. A logical approach for determining which allergens should be included would involve consulting a local allergy expert initially to identify a limited number of allergens that are important in that area [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of chronic NAR includes several other forms of rhinitis as well as laryngopharyngeal reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1949203\">",
"    <span class=\"h2\">",
"     Other forms of rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various other causes of rhinitis should be excluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perennial allergic rhinitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"       \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rhinitis medicamentosa (due to topical decongestants) and nasal dysfunction related to systemic medications (discussed in next section) (see",
"      <a class=\"local\" href=\"#H11252036\">",
"       'Medication-induced rhinitis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Occupational rhinitis (allergic and irritant) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=see_link\">",
"       \"Occupational rhinitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrophic rhinitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18519?source=see_link\">",
"       \"Atrophic rhinosinusitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasal polyposis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'CRS with nasal polyposis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rhinitis in association with hormonal changes of pregnancy, lactation, hypothyroidism, and acromegaly (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H6#H6\">",
"       \"An overview of rhinitis\", section on 'Other causes of rhinitis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11252036\">",
"    <span class=\"h3\">",
"     Medication-induced rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications can cause nasal congestion (",
"    <a class=\"graphic graphic_table graphicRef75862 \" href=\"UTD.htm?25/47/26364\">",
"     table 1",
"    </a>",
"    ). The most common form of medication-induced rhinitis is that caused by excessive use of over-the-counter decongestant nasal sprays, a disorder called rhinitis medicamentosa. Physical examination in patients with rhinitis medicamentosa often reveals swollen, red nasal mucous membranes. Diagnosis most heavily relies upon the history of use of a causative medication.",
"   </p>",
"   <p>",
"    In some patients, even several days of regular use of decongestant sprays leads to rebound nasal congestion as the medication wears off, prompting patients to administer the medicine more frequently to obtain relief. This begins a vicious cycle of nasal congestion both caused and temporarily relieved by the medication, with escalating use and eventual dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of rhinitis medicamentosa begins with withdrawal of the causative medication. In addition, an intranasal glucocorticoid is usually required to reduce symptoms while patients discontinue the culprit decongestant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. It is important to counsel patients that nasal congestion will probably worsen temporarily as the offending medication is stopped, so that this is not interpreted as treatment failure. Intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    was shown in a small randomized trial of 19 patients to be effective in countering rebound nasal congestion in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/76\">",
"     76",
"    </a>",
"    ]. Topical intranasal glucocorticoids achieve high concentrations of the drug in the affected mucosa and are the most appropriate long-term therapy. Complete recovery can take as long as one year in cases of long-term overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A brief course of oral glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 0.5 mg per kg for five days) has also been proposed for treatment during withdrawal in some case reports, and this is helpful when nasal congestion is sufficiently severe that topical therapies cannot penetrate up into the nose. However, this is not necessary in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1949210\">",
"    <span class=\"h2\">",
"     Laryngopharyngeal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated postnasal irritation and excessive phlegm can also result from reflux of gastric fluids, with or without esophageal symptoms noticeable to the patient, a condition referred to as laryngopharyngeal reflux. In a randomized trial of 75 patients with isolated postnasal drip, sinus disease and allergic rhinitis were excluded with a sinus CT and either skin testing or in vitro test allergy testing, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/83\">",
"     83",
"    </a>",
"    ]. Patients were assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    (30 mg twice daily) or placebo for 16 weeks. There was statistically significant improvement in symptoms in the group receiving lansoprazole at 8 and 16 weeks, which persisted at least to 2 months. The responders were not distinguishable from nonresponders either by pH or impedance monitoring at the start of the study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link\">",
"     \"Laryngopharyngeal reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic NAR are generally less responsive to pharmacologic therapy than those with allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/7,84\">",
"     7,84",
"    </a>",
"    ]. Specifically, most find oral antihistamines unhelpful [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. However, two classes of medications are useful in treating the total symptom-complex of chronic nonallergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/54,87-97\">",
"     54,87-97",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical intranasal glucocorticoids (INGCs)",
"     </li>",
"     <li>",
"      Topical antihistamine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide has been approved specifically to treat the symptom of rhinorrhea in chronic nonallergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Primary therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild disease may be adequately treated with either INGC or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    . There are no comparative studies specifically designed to compare the use of INGCs versus topical antihistamines for the treatment of NAR.",
"   </p>",
"   <p>",
"    Those with moderate to severe disease tend to respond better to the combination of an INGC and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1586851\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We generally use full-strength dosing for both agents and emphasize to patients that the medications should be used on a daily basis regardless of the presence or absence of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intranasal glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several INGC preparations have been shown to be effective for most patients in multiple randomized controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/89,90,92,101\">",
"     89,90,92,101",
"    </a>",
"    ]. Multiple preparations are available (",
"    <a class=\"graphic graphic_table graphicRef55833 \" href=\"UTD.htm?16/18/16685\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The largest report demonstrating a positive treatment effect with INGC was a combined analysis of three double-blind, randomized, prospective, placebo-controlled studies of 983 patients with NAR with and without nasal eosinophilia (674 were classified as without nasal eosinophils) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/101\">",
"     101",
"    </a>",
"    ]. Intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate at a dose of 200 or 400 micrograms was significantly more effective than placebo in both groups, as assessed by total nasal symptom scores for nasal obstruction, postnasal drip, and rhinorrhea.",
"   </p>",
"   <p>",
"    However, not all patients with NAR respond to INGCs, and another large study showed no significant impact on symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/7\">",
"     7",
"    </a>",
"    ]. A subsequent multicenter trial was performed to assess the effects of INGC therapy on a subset of patients with symptoms that were triggered predominantly by changes in weather and temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/102\">",
"     102",
"    </a>",
"    ]. In this randomized study, 699 patients with NAR triggered by these factors were treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    furoate or placebo for four weeks. There were no significant differences between the two therapies. Thus, although patients with NAR as a group derive benefit from INGCs, there are clearly important subgroups of nonresponders that require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Topical antihistamine sprays",
"    </span>",
"    &nbsp;&mdash;&nbsp;We usually begin with full-strength dosing using one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"       Azelastine",
"      </a>",
"      0.15 percent (Astepro, containing 205 mcg per actuation), one to two actuations per nostril twice daily and decreasing the dose as symptoms improve. Many patients&rsquo; symptoms are controlled with once daily dosing.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"       Azelastine",
"      </a>",
"      is also available in a 0.1 percent preparation (Astelin, containing 137 mcg per actuation) as well as a generic preparation that is dosed two actuations each nostril twice daily in adults and one actuation twice daily in children.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/25/33168?source=see_link\">",
"       Olopatadine",
"      </a>",
"      hydrochloride nasal spray (0.06 percent) (Patanase, containing 665 mcg per actuation) that is dosed two actuations twice daily in adults and children &gt;12, and one actuation twice daily for children &le;11 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As monotherapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    has been shown to be effective in randomized controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/91,103\">",
"     91,103",
"    </a>",
"    ]. As an example, in two multicenter randomized open-label trials, approximately 80 to 85 percent of more than 200 subjects with chronic NAR responded favorably to azelastine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The improvement in symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    is likely due to antiinflammatory actions. This activity includes the ability to diminish eosinophil activation and adhesion molecule expression, and suppress inflammatory cytokine generation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/95,96,104\">",
"     95,96,104",
"    </a>",
"    ]. Azelastine may also reduce neurogenic excitation from olfactory stimuli. In the previously mentioned study in which subjects with NAR were exposed to pleasant and unpleasant odors, the administration of azelastine significantly attenuated exaggerated blood flow to odor-sensitive regions of the brain as assessed by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/25/33168?source=see_link\">",
"     Olopatadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    (0.1 percent) were compared for the treatment of NAR in a multicenter, randomized parallel group study lasting 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/105\">",
"     105",
"    </a>",
"    ]. Both reduced congestion, rhinorrhea, postnasal drip, and sneezing and there were no statistically significant differences between their effects. In addition, there was no difference in the side effect profile of the two agents. In another placebo-controlled study, olopatadine reduced the response to hyperosmolar challenge in patients with prominent vasomotor symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1586851\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been our clinical experience that the combination of INGCs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    is more effective than either agent alone, although this has not been specifically studied in chronic nonallergic rhinitis. Combination therapy can be achieved either by using two separate nasal sprays, or a combination product. A combination spray containing azelastine hydrochloride 137 mcg and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    propionate 50 mcg (Dymista) became available in the US in 2012 and is approved for children older than 12 years and adults for seasonal allergic rhinitis. The dose is one actuation per nostril, twice daily. This combination product has been studied in patients with seasonal allergic rhinitis and has been shown to be superior to single treatment with either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prominent rhinorrhea without other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;When rhinorrhea is the dominant symptom or the only symptom, as in gustatory rhinitis or rhinitis of the elderly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide (0.03 percent) nasal spray is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/35,108\">",
"     35,108",
"    </a>",
"    ]. Ipratropium bromide is usually employed at a dose of two sprays to each nostril three times a day. Alternatively, it can also be used as needed, or prior to exposures that cause rhinorrhea, such as cold air, or before eating. This medication is also available in a concentration of 0.06 percent, although this strength is intended for short-term use only (eg, treatment of rhinorrhea associated with the common cold). Two multicenter, placebo-controlled trials demonstrated the effectiveness of ipratropium bromide to control rhinorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide nasal spray (0.03 percent) for one year among 285 patients with perennial NAR resulted in significant improvement in rhinorrhea as well as a decreased need for additional medications to control symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 253 patients with perennial NAR,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      nasal spray significantly reduced rhinorrhea versus that observed with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive therapies that are helpful in some patients include oral decongestants, nasal saline sprays and irrigations, and oral antihistamines. Studies of anti-leukotriene drugs and intranasal chromones in the treatment of NAR are lacking.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oral decongestants",
"      </strong>",
"      : An oral decongestant, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      , can be added to the treatment regimen, unless symptoms related to prostatic hyperplasia or hypertension preclude their use. The usual dosing of pseudoephedrine is 30 or 60 mg orally, up to three times daily on symptomatic days.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       Phenylephrine",
"      </a>",
"      hydrochloride is also widely available, but it is less effective for the treatment of rhinitis symptoms, and may not be superior to placebo at the 10 mg dose that is commonly available without prescription [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/109,110\">",
"       109,110",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are no specific studies examining the clinical efficacy of decongestants for this NAR. Such agents are employed as needed only for congestion not responsive to the use of either the nasal glucocorticoid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      , or a combination of both.",
"     </li>",
"     <li>",
"      <strong>",
"       Nasal saline irrigation",
"      </strong>",
"      : Daily nasal lavage or nasal saline sprays can also be useful. These interventions are particularly helpful for symptoms of postnasal drainage. They can be used immediately prior to INGCs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      , so that the mucosa is freshly cleansed when the medications are applied (",
"      <a class=\"graphic graphic_table graphicRef71059 \" href=\"UTD.htm?42/33/43548\">",
"       table 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Nasal lavage is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed. A large body of observational reports and one prospective controlled clinical study has found that nasal lavage is effective in NAR, as well as chronic rhinosinusitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/111\">",
"       111",
"      </a>",
"      ]. In the only prospective study, the use of nasal irrigation significantly improved 23 of 30 nasal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/112\">",
"       112",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A variety of over-the-counter devices, including bulb syringes and bottle sprayers are effective, provided the system delivers an adequate volume of solution (&gt;200 mL per side) into the nose. Patients can make their own solutions or buy commercially-prepared kits. Nasal lavage with warmed saline can be performed as needed only, daily at baseline, or twice daily for increased symptoms.",
"      <br/>",
"      <br/>",
"      Intranasal saline sprays have also been found effective for symptoms of chronic NAR, including relieving postnasal drip, sneezing, and congestion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/54,113\">",
"       54,113",
"      </a>",
"      ]. Saline sprays are somewhat less effective than larger volume nasal lavage, although they may be more convenient for some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Oral antihistamines",
"      </strong>",
"      : Clinical experience and limited data suggest that the newer, nonsedating H1 antihistamines are not as effective in NAR, compared with allergic rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Older, first generation H1 antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/52/24390?source=see_link\">",
"       chlorpheniramine",
"      </a>",
"      ) have anticholinergic properties that can be helpful to some patients with persistent and bothersome postnasal drip",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anterior rhinorrhea despite the above therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/115\">",
"       115",
"      </a>",
"      ]. However, these medications are sedating and have other disadvantages that are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link&amp;anchor=H25107382#H25107382\">",
"       \"Pharmacotherapy of allergic rhinitis\", section on 'Oral antihistamines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Role of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several surgical approaches have been used in patients with severe chronic NAR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/108,116-119\">",
"     108,116-119",
"    </a>",
"    ]. These have been reported as uncontrolled case series. Such interventions can be considered in patients with difficult symptoms that do not respond to multiple therapies, such as topical nasal steroids in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"     azelastine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decongestants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide. Six to twelve months of medical management should be allowed before surgical options are considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A turbinectomy can be performed when congestion is predominant. With this technique, there has been concern about the destruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elimination of the mucosal surface. However, laser turbinectomy has been reported to preserve normal nasal cytology as well as normal ciliary activity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of other surgical procedures have been tried in the past, including vidian nerve resection, electrocoagulation of anterior ethmoidal nerve, and sphenopalatine ganglion block [",
"      <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/119,120\">",
"       119,120",
"      </a>",
"      ]. None of these techniques has been shown to have long-term benefits and the potential risks (eg, persistent pain) outweigh any possible benefits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1689286\">",
"    <span class=\"h2\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    has been shown to reduce the symptoms of NAR, but irritation of the nasal mucosa was a limiting factor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Subsequently, a randomized trial of 42 patients with a significant component of NAR, evaluated the effects of a diluted capsaicin nasal spray to which eucalyptol was added to reduce the burning sensation caused by capsaicin [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/123\">",
"     123",
"    </a>",
"    ]. After two weeks of therapy with this preparation (dosed up to 12 actuations daily), patients reported significant improvements in total nasal symptom scores compared to placebo and good tolerability. This preparation is available without a prescription [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/124\">",
"     124",
"    </a>",
"    ]. We do not have extensive experience with this product.",
"   </p>",
"   <p>",
"    Other alternative and complementary therapies have been evaluated, such as acupuncture and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , although these cannot be recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;We follow patients receiving chronic therapy for rhinitis every three to twelve months, depending upon the severity and nature of the symptoms. The medications regimen can be reduced in some patients over time. However, in most patients, some medication is usually needed on a daily and long-term basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic NAR is a persistent condition in the majority of patients. In one study, 180 patients with NAR were reevaluated three to seven years after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/61/12250/abstract/125\">",
"     125",
"    </a>",
"    ]. Fifty-two percent reported worsening symptoms. There was a statistically significant increase in the percentage of patients who had developed asthma (32 to 55 percent) and 11 percent had decrements in lung function compared to their initial evaluation. In addition, 24 percent had developed allergen specific IgE (most commonly to dust mite and animal epithelia). Thus, over time, chronic NAR may involve the lower airways in some patients, and can progress to allergic rhinitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24818?source=see_link\">",
"       \"Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonallergic rhinitis (NAR) is a syndrome in which some combination of sneezing, rhinorrhea, nasal congestion, and postnasal drainage is present over time, in the absence of a specific etiology. The pathogenesis is not well characterized. Other terms for this condition include vasomotor rhinitis, idiopathic rhinitis, nonallergic-noninfectious rhinitis, and intrinsic rhinitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As many as 50 percent of patients presenting with rhinitis may have the nonallergic form, either alone or in combination with allergic or other forms of rhinitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NAR can be best distinguished from other forms of rhinitis with a detailed clinical history. Compared with allergic rhinitis, NAR has a later age of onset (usually after age 20) and more prominent nasal congestion and postnasal drainage. Patients often identify weather conditions or nonspecific respiratory irritants (eg, cigarette smoke) as exacerbating factors. Symptoms of allergic conjunctivitis are absent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gustatory rhinitis is a subtype of NAR that presents as watery rhinorrhea in response to eating, particularly upon ingestion of heated or spicy foods. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is based upon characteristic historical features, physical exam findings, and the absence of evidence of sensitivity to aeroallergens. It is a diagnosis of exclusion, although it may coexist with other forms of rhinitis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild symptoms of NAR, we recommend either an intranasal glucocorticoid or an intranasal antihistamine spray (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Primary therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to severe symptoms, we suggest combination therapy with",
"      <strong>",
"       both",
"      </strong>",
"      intranasal glucocorticoids (",
"      <a class=\"graphic graphic_table graphicRef55833 \" href=\"UTD.htm?16/18/16685\">",
"       table 2",
"      </a>",
"      ) and intranasal antihistamines, rather than monotherapy with either agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We find that most patients require both agents daily for adequate symptom control. We start with full strength doses of both agents and reduce the doses over time as symptoms improve. A combination spray containing both glucocorticoid and antihistamine is also available. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Primary therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide for patients with prominent watery rhinorrhea without other symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Isolated rhinorrhea is typical of gustatory rhinitis and rhinitis of the elderly. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prominent rhinorrhea without other symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with NAR and prominent nasal congestion that is refractory to intranasal glucocorticoids (",
"      <a class=\"graphic graphic_table graphicRef55833 \" href=\"UTD.htm?16/18/16685\">",
"       table 2",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/15/33008?source=see_link\">",
"       azelastine",
"      </a>",
"      , or a combination of both, we suggest adding over-the-counter oral decongestants on an as-needed basis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       Pseudoephedrine",
"      </a>",
"      is commonly employed, but should be used with caution in patients with hypertension. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjunctive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend daily nasal lavage as an adjunctive therapy for those patients with NAR who find the maneuver comfortable (",
"      <a class=\"graphic graphic_table graphicRef71059 \" href=\"UTD.htm?42/33/43548\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Regular use of over-the-counter nasal saline sprays may also benefit some patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjunctive therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/1\">",
"      Blom HM, Godthelp T, Fokkens WJ, et al. Mast cells, eosinophils and IgE-positive cells in the nasal mucosa of patients with vasomotor rhinitis. An immunohistochemical study. Eur Arch Otorhinolaryngol 1995; 252 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/2\">",
"      Powe DG, Huskisson RS, Carney AS, et al. Evidence for an inflammatory pathophysiology in idiopathic rhinitis. Clin Exp Allergy 2001; 31:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/3\">",
"      Bousquet J, Fokkens W, Burney P, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy 2008; 63:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/4\">",
"      Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/5\">",
"      van Rijswijk JB, Blom HM, Fokkens WJ. Idiopathic rhinitis, the ongoing quest. Allergy 2005; 60:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/6\">",
"      Numata T, Konno A, Hasegawa S, et al. Pathophysiological features of the nasal mucosa in patients with idiopathic rhinitis compared to allergic rhinitis. Int Arch Allergy Immunol 1999; 119:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/7\">",
"      Blom HM, Godthelp T, Fokkens WJ, et al. The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis. J Allergy Clin Immunol 1997; 100:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/8\">",
"      MALCOMSON KG. The vasomotor activities of the nasal mucous membrane. J Laryngol Otol 1959; 73:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/9\">",
"      Jones AS, Lancer JM. Vasomotor rhinitis. Br Med J (Clin Res Ed) 1987; 294:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/10\">",
"      Wilde AD, Cook JA, Jones AS. The nasal response to isometric exercise. Clin Otolaryngol Allied Sci 1995; 20:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/11\">",
"      Wolf G. [New aspects in the pathogenesis and therapy of hyperreflexive rhinopathy]. Laryngol Rhinol Otol (Stuttg) 1988; 67:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/12\">",
"      Moneret-Vautrin DA, Hsieh V, Wayoff M, et al. Nonallergic rhinitis with eosinophilia syndrome a precursor of the triad: nasal polyposis, intrinsic asthma, and intolerance to aspirin. Ann Allergy 1990; 64:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/13\">",
"      Baraniuk JN. Neural control of human nasal secretion. Pulm Pharmacol 1991; 4:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/14\">",
"      Lundblad L, Hua XY, Lundberg JM. Mechanisms for reflexive hypertension induced by local application of capsaicin and nicotine to the nasal mucosa. Acta Physiol Scand 1984; 121:277.",
"     </a>",
"    </li>",
"    <li>",
"     Lacrois JS, Pochon N, Lundberg JM. Increased concentration of sensory neuropeptide in the nasal mucosa from patients with nonallergic chronic rhinitis. In: The new frontier of otorhinolaryngology in Europe, Passall D (Ed), Monduzzi Editore, Sorrento, Italy 1992. p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/16\">",
"      Borson DB. Roles of neutral endopeptidase in airways. Am J Physiol 1991; 260:L212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/17\">",
"      Trotter CM, Hall GH, Salter DM, Wilson JA. Histology of mucous membrane of human inferior nasal concha. Clin Anat 1990; 3:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/18\">",
"      Berger G, Goldberg A, Ophir D. The inferior turbinate mast cell population of patients with perennial allergic and nonallergic rhinitis. Am J Rhinol 1997; 11:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/19\">",
"      Bachert C, Prohaska P, Pipkorn U. IgE-positive mast cells on the human nasal mucosal surface in response to allergen exposure. Rhinology 1990; 28:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/20\">",
"      Otsuka H, Inaba M, Fujikura T, Kunitomo M. Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis: studies of nasal scrapings and their dispersed cells. J Allergy Clin Immunol 1995; 96:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/21\">",
"      Fokkens WJ, Godthelp T, Holm AF, et al. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study. Clin Exp Allergy 1992; 22:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/22\">",
"      Ying S, Durham SR, Jacobson MR, et al. T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. Immunology 1994; 82:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/23\">",
"      Varney VA, Jacobson MR, Sudderick RM, et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis 1992; 146:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/24\">",
"      Godthelp T, Holm AF, Fokkens WJ, et al. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study. J Allergy Clin Immunol 1996; 97:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/25\">",
"      Connell JT. Nasal mastocytosis. J Allergy 1969; 43:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/26\">",
"      Drake-Lee AB, Moriarty B, Smallman LA. Mast cell numbers in the mucosa of the inferior turbinate in patients with perennial allergic rhinitis: a light microscopic study. J Laryngol Otol 1991; 105:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/27\">",
"      Ruhno J, Howie K, Anderson M, et al. The increased number of epithelial mast cells in nasal polyps and adjacent turbinates is not allergy-dependent. Allergy 1990; 45:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/28\">",
"      Malm L, Wihl JA, Lamm CJ, Lindqvist N. Reduction of metacholine-induced nasal secretion by treatment with a new topical steroid in perennial non-allergic rhinitis. Allergy 1981; 36:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/29\">",
"      Humbert M, Menz G, Ying S, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/30\">",
"      Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996; 153:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/31\">",
"      Kroegel C, J&auml;ger L, Walker C. Is there a place for intrinsic asthma as a distinct immunopathological entity? Eur Respir J 1997; 10:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/32\">",
"      Togias AG, Proud D, Lichtenstein LM, et al. The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air. Am Rev Respir Dis 1988; 137:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/33\">",
"      Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000; 55 Suppl 64:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/34\">",
"      Bernstein JA, Hastings L, Boespflug EL, et al. Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine. Ann Allergy Asthma Immunol 2011; 106:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/35\">",
"      Raphael G, Raphael MH, Kaliner M. Gustatory rhinitis: a syndrome of food-induced rhinorrhea. J Allergy Clin Immunol 1989; 83:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/36\">",
"      Papon JF, Brugel-Ribere L, Fodil R, et al. Nasal wall compliance in vasomotor rhinitis. J Appl Physiol 2006; 100:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/37\">",
"      Iguchi Y, Yao K, Okamoto M. A characteristic protein in nasal discharge differentiating non-allergic chronic rhinosinusitis from allergic rhinitis. Rhinology 2002; 40:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/38\">",
"      Maselli Del Giudice A, Barbara M, Russo GM, et al. Cell-mediated non-allergic rhinitis in children. Int J Pediatr Otorhinolaryngol 2012; 76:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/39\">",
"      Matteo G, Luigi MG, Amelia L, et al. Nasal cytology in children: recent advances. Ital J Pediatr 2012; 38:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/40\">",
"      KleinJan A, Vinke JG, Severijnen LW, Fokkens WJ. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J 2000; 15:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/41\">",
"      Rond&oacute;n C, Romero JJ, L&oacute;pez S, et al. Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clin Immunol 2007; 119:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/42\">",
"      Rond&oacute;n C, Fern&aacute;ndez J, L&oacute;pez S, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. J Allergy Clin Immunol 2009; 124:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/43\">",
"      Rond&oacute;n C, Campo P, Togias A, et al. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol 2012; 129:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/44\">",
"      Smurthwaite L, Walker SN, Wilson DR, et al. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur J Immunol 2001; 31:3422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/45\">",
"      Smurthwaite L, Durham SR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/46\">",
"      Rond&oacute;n C, Campo P, Herrera R, et al. Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis. J Allergy Clin Immunol 2011; 128:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/47\">",
"      Rond&oacute;n C, Campo P, Galindo L, et al. Prevalence and clinical relevance of local allergic rhinitis. Allergy 2012; 67:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/48\">",
"      Wierzbicki DA, Majmundar AR, Schull DE, Khan DA. Multiallergen nasal challenges in nonallergic rhinitis. Ann Allergy Asthma Immunol 2008; 100:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/49\">",
"      Middleton E Jr. Chronic rhinitis in adults. J Allergy Clin Immunol 1988; 81:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/50\">",
"      Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980; 65:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/51\">",
"      Enberg RN. Perennial nonallergic rhinitis: a retrospective review. Ann Allergy 1989; 63:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/52\">",
"      Leynaert B, Bousquet J, Neukirch C, et al. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/53\">",
"      Togias A. Age relationships and clinical features of nonallergic rhinitis. J Allergy Clin Immunol 1990; 85:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/54\">",
"      Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol 2001; 86:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/55\">",
"      Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.",
"     </a>",
"    </li>",
"    <li>",
"     Togias AK. Nonallergic rhinitis. In: Allergic and nonallergic rhinitis: clinical aspects, Mygine N, Naclerio RM (Eds), Munksgaard, Copenhagen 1993. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/57\">",
"      Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol 2007; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/58\">",
"      Berger WE, Schonfeld JE. Nonallergic rhinitis in children. Curr Allergy Asthma Rep 2007; 7:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/59\">",
"      Chawes BL, Kreiner-M&oslash;ller E, Bisgaard H. Objective assessments of allergic and nonallergic rhinitis in young children. Allergy 2009; 64:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/60\">",
"      Erwin EA, Faust RA, Platts-Mills TA, Borish L. Epidemiological analysis of chronic rhinitis in pediatric patients. Am J Rhinol Allergy 2011; 25:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/61\">",
"      Westman M, Stj&auml;rne P, Asarnoj A, et al. Natural course and comorbidities of allergic and nonallergic rhinitis in children. J Allergy Clin Immunol 2012; 129:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/62\">",
"      Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006; 61:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/63\">",
"      M&oslash;lgaard E, Thomsen SF, Lund T, et al. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. Allergy 2007; 62:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/64\">",
"      Settipane RA. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc 2003; 24:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/65\">",
"      Settipane GA, Klein DE. Non allergic rhinitis: demography of eosinophils in nasal smear, blood total eosinophil counts and IgE levels. N Engl Reg Allergy Proc 1985; 6:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/66\">",
"      Kaliner MA. Nonallergic rhinopathy (formerly&nbsp;known as vasomotor rhinitis). Immunol Allergy Clin North Am 2011; 31:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/67\">",
"      Lindberg S, Malm L. Comparison of allergic rhinitis and vasomotor rhinitis patients on the basis of a computer questionnaire. Allergy 1993; 48:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/68\">",
"      Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991; 46:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/69\">",
"      Rolla G, Guida G, Heffler E, et al. Diagnostic classification of persistent rhinitis and its relationship to exhaled nitric oxide and asthma: a clinical study of a consecutive series of patients. Chest 2007; 131:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/70\">",
"      Bernstein JA, Salapatek AM, Lee JS, et al. Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model. Allergy Asthma Proc 2012; 33:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/71\">",
"      Duran-Tauleria E, Vignati G, Guedan MJ, Petersson CJ. The utility of specific immunoglobulin E measurements in primary care. Allergy 2004; 59 Suppl 78:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/72\">",
"      Mansfield L, Hutteman HR, Tyson S, Enriquez A. A multiallergen and miniscreen can change primary care provider diagnosis and treatment of rhinitis. Am J Rhinol Allergy 2012; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/73\">",
"      Ahlstedt S, Murray CS. In vitro diagnosis of allergy: how to interpret IgE antibody results in clinical practice. Prim Care Respir J 2006; 15:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/74\">",
"      Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2012; 67:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/75\">",
"      Kwong KY, Eghrari-Sabet JS, Mendoza GR, et al. The benefits of specific immunoglobulin E testing in the primary care setting. Am J Manag Care 2011; 17 Suppl 17:S447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/76\">",
"      Vaidyanathan S, Williamson P, Clearie K, et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/77\">",
"      Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006; 16:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/78\">",
"      Pass&agrave;li D, Salerni L, Pass&agrave;li GC, et al. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf 2006; 5:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/79\">",
"      Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med 2005; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/80\">",
"      Doshi J. Rhinitis medicamentosa: what an otolaryngologist needs to know. Eur Arch Otorhinolaryngol 2009; 266:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/81\">",
"      Hall&eacute;n H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy 1997; 27:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/82\">",
"      Graf PM, Hall&eacute;n H. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal. Am J Rhinol 1997; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/83\">",
"      Vaezi MF, Hagaman DD, Slaughter JC, et al. Proton pump inhibitor therapy improves symptoms in postnasal drainage. Gastroenterology 2010; 139:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/84\">",
"      Philip G, Togias AG. Nonallergic rhinitis. Pathophysiology and models for study. Eur Arch Otorhinolaryngol 1995; 252 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/85\">",
"      Mullarkey MF. Eosinophilic nonallergic rhinitis. J Allergy Clin Immunol 1988; 82:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/86\">",
"      Rinne J, Simola M, Malmberg H, Haahtela T. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002; 109:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/87\">",
"      Kondo H, Nachtigal D, Frenkiel S, et al. Effect of steroids on nasal inflammatory cells and cytokine profile. Laryngoscope 1999; 109:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/88\">",
"      Malm L, Wihl JA. Intra-nasal beclomethasone dipropionate in vasomotor rhinitis. Acta Allergol 1976; 31:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/89\">",
"      Wight RG, Jones AS, Beckingham E, et al. A double blind comparison of intranasal budesonide 400 micrograms and 800 micrograms in perennial rhinitis. Clin Otolaryngol Allied Sci 1992; 17:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/90\">",
"      Small P, Black M, Frenkiel S. Effects of treatment with beclomethasone dipropionate in subpopulations of perennial rhinitis patients. J Allergy Clin Immunol 1982; 70:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/91\">",
"      Banov CH, Lieberman P, Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 2001; 86:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/92\">",
"      Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995; 25:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/93\">",
"      Pipkorn U, Berge T. Long-term treatment with budesonide in vasomotor rhinitis. Acta Otolaryngol 1983; 95:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/94\">",
"      Takao A, Shimoda T, Matsuse H, et al. Inhibitory effects of azelastine hydrochloride in alcohol-induced asthma. Ann Allergy Asthma Immunol 1999; 82:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/95\">",
"      Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996; 98:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/96\">",
"      Yoneda K, Yamamoto T, Ueta E, Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn J Pharmacol 1997; 73:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/97\">",
"      Tamaoki J, Yamawaki I, Tagaya E, et al. Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways. Am J Physiol 1999; 276:L351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/98\">",
"      Grossman J, Banov C, Boggs P, et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol 1995; 95:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/99\">",
"      Bronsky EA, Druce H, Findlay SR, et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol 1995; 95:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/100\">",
"      Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010; 105:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/101\">",
"      Webb DR, Meltzer EO, Finn AF Jr, et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol 2002; 88:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/102\">",
"      Jacobs R, Lieberman P, Kent E, et al. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. Allergy Asthma Proc 2009; 30:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/103\">",
"      Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin 2005; 21:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/104\">",
"      Lieberman P. Intranasal antihistamines for allergic rhinitis: mechanism of action. Allergy Asthma Proc 2009; 30:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/105\">",
"      Lieberman P, Meltzer EO, LaForce CF, et al. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. Allergy Asthma Proc 2011; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/106\">",
"      Smith PK, Collins J. Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis. Am J Rhinol Allergy 2011; 25:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/107\">",
"      Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012; 129:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/108\">",
"      Georgalas C, Jovancevic L. Gustatory rhinitis. Curr Opin Otolaryngol Head Neck Surg 2012; 20:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/109\">",
"      Hatton RC, Winterstein AG, McKelvey RP, et al. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother 2007; 41:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/110\">",
"      Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2009; 102:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/111\">",
"      Harvey R, Hannan SA, Badia L, Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev 2007; :CD006394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/112\">",
"      Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/113\">",
"      Spector SL. The placebo effect is nothing to sneeze at. J Allergy Clin Immunol 1992; 90:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/114\">",
"      Pynnonen MA, Mukerji SS, Kim HM, et al. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg 2007; 133:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/115\">",
"      Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995; 95:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/116\">",
"      el-Guindy A. Endoscopic transseptal vidian neurectomy. Arch Otolaryngol Head Neck Surg 1994; 120:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/117\">",
"      Dong Z. [Anterior ethmoidal electrocoagulation in the treatment of vasomotor rhinitis]. Zhonghua Er Bi Yan Hou Ke Za Zhi 1991; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/118\">",
"      Mladina R, Risavi R, Subaric M. CO2 laser anterior turbinectomy in the treatment of non-allergic vasomotor rhinopathia. A prospective study upon 78 patients. Rhinology 1991; 29:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/119\">",
"      Fernandes CM. Bilateral transnasal vidian neurectomy in the management of chronic rhinitis. J Laryngol Otol 1994; 108:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/120\">",
"      Prasanna A, Murthy PS. Vasomotor rhinitis and sphenopalatine ganglion block. J Pain Symptom Manage 1997; 13:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/121\">",
"      Blom HM, Van Rijswijk JB, Garrelds IM, et al. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. Clin Exp Allergy 1997; 27:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/122\">",
"      Marabini S, Ciabatti PG, Polli G, et al. Beneficial effects of intranasal applications of capsaicin in patients with vasomotor rhinitis. Eur Arch Otorhinolaryngol 1991; 248:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/123\">",
"      Bernstein JA, Davis BP, Picard JK, et al. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol 2011; 107:171.",
"     </a>",
"    </li>",
"    <li>",
"     Marketed as Sinus Buster in the United States",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/61/12250/abstract/125\">",
"      Rond&oacute;n C, Do&ntilde;a I, Torres MJ, et al. Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis. J Allergy Clin Immunol 2009; 123:1098.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7532 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12250=[""].join("\n");
var outline_f11_61_12250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Noninflammatory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inflammatory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Evidence for a localized allergic response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1685189\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1685104\">",
"      Characteristic triggers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHYSICAL EXAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4107301\">",
"      Referral for allergy testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1949203\">",
"      Other forms of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11252036\">",
"      - Medication-induced rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1949210\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Primary therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intranasal glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Topical antihistamine sprays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1586851\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prominent rhinorrhea without other symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Role of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1689286\">",
"      Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/47/26364\" title=\"table 1\">",
"      Causes of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/18/16685\" title=\"table 2\">",
"      Glucocorticoid nasal sprays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43548\" title=\"table 3\">",
"      Nasal irrigation instruct",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18519?source=related_link\">",
"      Atrophic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/15/24818?source=related_link\">",
"      Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_61_12251="Fatty acid oxidation enzymes";
var content_f11_61_12251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fatty acid oxidation enzymes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Short-chain acyl-CoA dehydrogenase (SCAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Medium-chain acyl-CoA dehydrogenase (MCAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Long-chain acyl-CoA dehydrogenase (LCAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Very long-chain acyl-CoA dehydrogenase (VLCAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Enoyl-CoA hydratase (crotonase)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Long-chain enoyl-CoA hydratase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Long-chain L-3-hydroxyacyl-CoA dehydrogenase (LCHAD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Acetyoacetyl-CoA thiolase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Long-chain 3-ketoacyl-CoA thiolase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Trifunctional enzyme (combines activities of 6, 8, and 10)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12251=[""].join("\n");
var outline_f11_61_12251=null;
var title_f11_61_12252="Left vs right ventricular MI";
var content_f11_61_12252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differences between left and right ventricular myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Left ventricular MI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Right ventricular MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"4\">",
"        Clinical features",
"       </td>",
"       <td>",
"        Pulmonary congestion",
"       </td>",
"       <td>",
"        Clear lung fields",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third and fourth heart sounds",
"       </td>",
"       <td>",
"        Right-sided third heart sound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New mitral regurgitation",
"       </td>",
"       <td>",
"        New tricuspid regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hypotension with distended neck veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"3\">",
"        Electrocardiogram",
"       </td>",
"       <td>",
"        ST elevation in standard leads",
"       </td>",
"       <td>",
"        ST elevation in V4R",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Commonly associated with inferior MI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Frequent atrioventricular block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Hemodynamic findings",
"       </td>",
"       <td>",
"        Increased pulmonary capillary wedge pressure (PCWP)",
"       </td>",
"       <td>",
"        Right atrial pressure (RAP) &ge;10 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        RAP:PCWP &ge;0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"4\">",
"        Specific management",
"       </td>",
"       <td>",
"        Fluid restriction",
"       </td>",
"       <td>",
"        Fluid resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preload and afterload reduction",
"       </td>",
"       <td>",
"        Avoid preload reduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reperfusion therapy",
"       </td>",
"       <td>",
"        Reperfusion therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inotropic agents, if necessary",
"       </td>",
"       <td>",
"        Inotropic agents, if necessary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12252=[""].join("\n");
var outline_f11_61_12252=null;
var title_f11_61_12253="Emergency medical kit for airlines";
var content_f11_61_12253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Emergency medical kit for airlines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Medications",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Epinephrine 1:1000",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antihistamine*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Dextrose 50 percent* 50 ml (or equivalent)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Nitroglycerin tablets or spray",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Major analgesic, injectable or oral",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sedative anticonvulsant*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antiemetic*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Bronchial dilator inhaler",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Atropine*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Adrenocortical steroid*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Diuretic*",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Medication for postpartum bleeding",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sodium chloride 0.9 percent (minimum 250 ml)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Acetyl Salicylic Acid for oral use",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Oral beta blocker",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           List of medications - generic name, plus trade name if indicated on the item",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Equipment",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Stethoscope",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sphygmomanometer (electronic preferred)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Airways, oropharyngeal (appropriate range of sizes)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Syringes (appropriate range of sizes)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Needles (appropriate range of sizes)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           IV catheters (appropriate range of sizes)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antiseptic wipes",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Gloves (disposable)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sharps disposal box",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Urinary catheter",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           System for delivering intravenous fluid",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Venous tourniquet",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sponge gauze",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Tape adhesive",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Surgical mask",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Flashlight and batteries (operator may decide to have one per aircraft in an easily accessible location)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Thermometer (non-mercury)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Emergency tracheal catheter (or large gauge intravenous cannula)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Umbilical cord clamp",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Basic Life Support cards",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Bag-valve mask",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           List of equipment",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Advanced Life Support cards",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    If a cardiac monitor (with or without defibrillator) is available, add to the above list: Epinephrine 1:10000 (can be a dilution of epinephrine 1:1000).",
"    <div class=\"footnotes\">",
"     * Injectable.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aerospace Medical Association Air Transport Medicine Committee. Emergency Medical Kit for Commercial Airlines: an Update. Aviation, Space, and Environmental Medicine 2007; 78:1170. Copyright &copy;2007 Aerospace Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12253=[""].join("\n");
var outline_f11_61_12253=null;
var title_f11_61_12254="Drugs that may worsen MG";
var content_f11_61_12254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that may unmask or exacerbate myasthenia gravis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anesthetic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloroprocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diazepam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ether",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Halothane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ketamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lidocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuromuscular blocking agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propanidid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antibiotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Aminoglycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Amikacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gentamicin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Kanamycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Neomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Netilmicin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Paromomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Spectinomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Streptomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tobramycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Fluoroquinolones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ciprofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gemifloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Levofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Moxifloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Norfloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Others",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ampicillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clarithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clindamycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Colistin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Erythromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lincomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Quinine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Telithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tetracyclines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anticonvulsants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gabapentin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenytoin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethadione",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antipsychotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorpromazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenothiazines",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antirheumatic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chloroquine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiovascular drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bretylium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Procainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propafenone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Verapamil and calcium channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Glucocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticotropin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methylprednisolone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prednisone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neuromuscular blockers and muscle relaxants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Botulinum toxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Magnesium sulfate and magnesium salts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methocarbamol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ophthalmologic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Betaxolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Echothiophate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Timolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tropicamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Proparacaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticholinergics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carnitine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholinesterase inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Deferoxamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Emetine (Ipecac syrup)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferon alpha",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iodinated contrast agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Narcotics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oral contraceptives",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oxytocin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ritonavir and antiretroviral protease inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Statins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyroxine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Drugs listed here should be used with caution in patients with myasthenia gravis. Aminoglycosides should be used only if absolutely necessary with close monitoring. Please refer to the text for further information.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12254=[""].join("\n");
var outline_f11_61_12254=null;
var title_f11_61_12255="Colonic stent barium enema";
var content_f11_61_12255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barium enema in a patient with a colonic stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema showing an expandable metal stent deployed in the colon. A \"waist\" is visible in the central part of the stent (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Naresh Gunaratnam, MD, Todd Baron, MD, and Miriam Thomas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_61_12255=[""].join("\n");
var outline_f11_61_12255=null;
